Functional Antibody Fragment Complementation for a Two-Components System for Redirected Killing of Unwanted Cells

ABSTRACT

A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targeting moiety that is the same or different from the targeting moiety in the agent.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No.15/355,511, filed Nov. 18, 2016, which claims the benefit of priority ofU.S. Provisional Application No. 62/257,552, filed Nov. 19, 2015, andU.S. Provisional Application No. 62/270,907, filed Dec. 22, 2015, eachof which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

The present application is filed with a Sequence Listing in electronicformat. The Sequence Listing is provided as a file entitled“2017-04-19_01131-0007-00US_SL_ST25.txt” created on Apr. 19, 2017, whichis 84,197 bytes in size.

FIELD

This application relates to targeted T-cell engaging agents for treatinga condition characterized by the presence of unwanted cells. Inparticular, it relates to agents that can be used to treat a conditioncharacterized by the presence of unwanted cells, such as cancer or otherdisease-causing cells.

BACKGROUND

Cancer and other diseases caused by the presence of unwanted cellscreate significant loss of life, suffering, and economic impact.Immunotherapeutic strategies for targeting cancer have been an activearea of translational clinical research.

A variety of other approaches have been explored for immunotherapy, butmany of these prior approaches lack sufficient specificity to particularunwanted cells. For example, demibodies have been designed each havingan scFv portion binding to different antigens on a target cell, an Fcdomain allowing pairing to a complementary demibody, and a bindingpartner capable of forming an association to another binding partner ona complementary demibody. WO 2007/062466. These demibodies, however, arenot necessarily specific to cancer cells and could bind and haveactivity on other cells expressing the same antigens. See also WO2013/104804, which provides a first polypeptide with a targeting moietybinding to a first antigen and a first fragment of a functional domain,along with a second polypeptide with a targeting moiety binding to asecond antigen and a second fragment of a functional domain that iscomplementary to the first fragment of the functional domain. Likewise,this approach is not necessarily specific to cancer cells and could bindand have activity on other cells expressing the same antigens.

While some positive test data has been shown with prior approaches,clinically-effective therapeutic strategies must be able to elicit astrong immune response in an individual suffering from a disease such ascancer. Additionally, effective therapies should be very specific andnot cause unwanted side effects to other cell types in the body.Therefore, additional developments in this field of re-directedimmunotherapy are required.

SUMMARY

In accordance with the description, the inventors describe a targetedT-cell engaging agent for treating a condition characterized by thepresence of unwanted cells. This agent includes (a) a targeting moietythat is capable of targeting the unwanted cells; (b) a first T-cellengaging domain capable of activity when binding a second T-cellengaging domain, wherein the second T-cell engaging domain is not partof the agent; (c) at least one inert binding partner capable of bindingthe first T-cell engaging domain such that the first T-cell engagingdomain does not bind to the second T-cell engaging domain unless theinert binding partner is removed; and (d) at least one cleavage siteseparating the first T-cell engaging domain and the inert bindingpartner.

In one embodiment, a two-component system for treating a conditioncharacterized by the presence of unwanted cells is encompassedcomprising a first component comprising a targeted T-cell engaging agentcomprising:

a. a first component comprising a targeted T-cell engaging agentcomprising:

-   -   i. a first targeting moiety that is capable of targeting the        unwanted cells;    -   ii. a first T-cell engaging domain capable of T-cell engaging        activity when binding a second T-cell engaging domain, wherein        the second T-cell engaging domain is not part of the first        component;    -   iii. a first inert binding partner for the first T-cell engaging        domain binding to the first T-cell engaging domain such that the        first T-cell engaging domain does not bind to the second T-cell        engaging domain unless the inert binding partner is removed; and    -   iv. a cleavage site separating the first T-cell engaging domain        and the first inert binding partner, wherein the cleavage site        is:        -   (1) cleaved by an enzyme expressed by the unwanted cells;        -   (2) cleaved through a pH-sensitive cleavage reaction inside            the unwanted cell;        -   (3) cleaved by a complement-dependent cleavage reaction; or        -   (4) cleaved by a protease that is colocalized to the            unwanted cell by a targeting moiety that is the same or            different from the targeting moiety in the agent,

b. a second component comprising a second T-cell engaging domain capableof T-cell engaging activity when binding the first T-cell engagingdomain, wherein the first and second T-cell engaging domains are capableof binding when neither is bound to an inert binding partner.

In another embodiment, the second component of the two-component systemfurther comprises a second targeting moiety that is capable of targetingthe unwanted cells.

In another embodiment, the second component of the two-component systemfurther comprises a second inert binding partner for the second T-cellengaging domain binding to the second T-cell engaging domain such thatthe second T cell engaging domain does not bind to the first T-cellengaging domain unless the inert binding partner is removed and

-   -   a. a cleavage site separating the second T-cell engaging domain        and the second inert binding partner, wherein the cleavage site        is:        -   i. cleaved by an enzyme expressed by the unwanted cells;        -   ii. cleaved through a pH-sensitive cleavage reaction inside            the unwanted cell;        -   iii. cleaved by a complement-dependent cleavage reaction; or        -   iv. cleaved by a protease that is colocalized to the            unwanted cell by a targeting moiety that is the same or            different from the targeting moiety in the agent,            wherein cleavage of the cleavage site causes loss of the            inert binding partner and complementation with the first            T-cell engaging domain of the two-component system.

In some embodiments, the first and second targeting moieties of thetwo-component system are the same.

In some embodiments, the first and second targeting moieties of thetwo-component system are different

In some embodiments, the first and second cleavage sites are the same.

In some embodiments, the first and second cleavage sites are different.

In some embodiments, at least one cleavage site is a protease cleavagesite. In some embodiments, the at least one cleavage site is capable ofbeing cleaved outside the unwanted cells.

In some embodiments of the two-component system, at least one enzymeexpressed by the unwanted cells is a protease.

In some embodiments of the two-component system, at least one inertbinding partner specifically binds the T-cell engaging domain.

In some embodiments of the two-component system, at least one inertbinding partner is a VH or VL domain.

In some embodiments of the two-component system, the T-cell engagingdomain is a VH domain, the inert binding partner is a VL domain and whenthe T-cell engaging domain is a VL domain, the inert binding partner isa VH domain.

In some embodiments of the two-component system, at least one targetingmoiety is an antibody or functional fragment thereof. In someembodiments of the two-component system, the at least one inert bindingpartner is capable of dissociation once at least one cleavage site hasbeen cleaved and after dissociation the two T-cell engaging domains arecapable of binding to each other and exhibiting T-cell engagingactivity.

In some embodiments of the two-component system, a set of nucleic acidmolecules encodes the first and second component of the two-componentsystem. In some embodiments of the two-component system, a nucleic acidmolecule encodes the component for use in a two-component system.

In some embodiments of the two-component system, one T-cell engagingdomain is a VH domain and the other T-cell engaging domain is a VLdomain.

In another embodiment, a component for use in a two-component system fortreating a condition characterized by the presence of unwanted cellscomprising a first targeted T-cell engaging agent comprises:

-   -   a. a targeting moiety that is capable of targeting the unwanted        cells;    -   b. a first T-cell engaging domain capable of T-cell engaging        activity when binding a second T-cell engaging domain, wherein        the second T-cell engaging domain is not part of the first        targeted T-cell engaging agent;    -   c. an inert binding partner for the first T-cell engaging domain        binding to the first T-cell engaging domain such that the first        T-cell engaging domain does not bind to the second T-cell        engaging domain unless the inert binding partner is removed; and    -   d. a cleavage site separating the first T-cell engaging domain        and the inert binding partner, wherein the cleavage site is:        -   i. cleaved by an enzyme expressed by the unwanted cells;        -   ii. cleaved through a pH-sensitive cleavage reaction inside            the unwanted cell;        -   iii. cleaved by a complement-dependent cleavage reaction; or            cleaved by a protease that is colocalized to the unwanted            cell by a targeting moiety that is the same or different            from the targeting moiety in the agent, wherein cleavage of            the cleavage site causes loss of the inert binding partner            and allows for complementation with the second T-cell            engaging domain that is not part of the agent.

In some embodiments, a method of treating a disease in a patientcharacterized by the presence of unwanted cells is encompassed thatcomprises administering the two-component system to the patient. In someembodiments, a method of targeting an immune response of a patient tounwanted cells is encompassed that comprises administering thetwo-component system. In some embodiments, these unwanted cells arecancer cells. In some embodiments, the cancer is any one of breastcancer, ovarian cancer, endometrial cancer, cervical cancer, bladdercancer, renal cancer, melanoma, lung cancer, prostate cancer, testicularcancer, thyroid cancer, brain cancer, esophageal cancer, gastric cancer,pancreatic cancer, colorectal cancer, liver cancer, leukemia, myeloma,nonHodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia, acutelymphoblastic leukemia, chronic lymphoblastic leukemia,lymphoproliferative disorder, myelodysplastic disorder,myeloproliferative disease or premalignant disease.

Additional objects and advantages will be set forth in part in thedescription which follows, and in part will be obvious from thedescription, or may be learned by practice. The objects and advantageswill be realized and attained by means of the elements and combinationsparticularly pointed out in the appended claims.

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive of the claims.

The accompanying drawings, which are incorporated in and constitute apart of this specification, illustrate one (several) embodiment(s) andtogether with the description, serve to explain the principles describedherein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows one embodiment of a first component of a two-componentsystem, where the first component is a targeted T-cell engaging agent inan inactive state with an inert binding partner.

FIG. 2 shows the process by which the cleavable linker is cleaved andthe inert binding partner is released to create an active entity.

FIG. 3 illustrates the creation of an active targeted, T-cell engagingagent after the inert binding partner is released from a pair ofcomplementary components in a two-component system.

FIGS. 4A-C illustrate the cleavage of the stepwise process of the pairof complementary components in a two-component system binding to thetarget cell (A), cleavage of linker attaching the inert binding partners(A and B), and binding to create an active moiety capable of T-cell

FIGS. 5A-B provide evaluation of constructs by SDS PAGE and Coomassieblue staining.

FIG. 6 shows IFNγ expression as a proxy for T cell response when cancercells were treated with various individual constructs and combinations,with 6245 serving as a positive control and the combination of 6248 and6249 showing beneficial results.

FIG. 7 shows IFNγ expression as a proxy for T cell response when cancercells were treated with various individual constructs and combinations,with 6245 as a positive control and the combination of 6248 and 6249showing beneficial results.

FIG. 8 shows IFNγ expression as a proxy for T cell response when cancercells were treated with different concentrations of constructs, with6245 as a positive control and the combination of 6248 and 6249 showingbeneficial results.

FIGS. 9A-B shows IFNγ expression as a proxy for T cell response whencancer cells were treated with controls or different concentrations ofconstructs, with 6245 as a positive control and the combination of 6248and 6249 showing beneficial results. PHA also served as a positivecontrol for nonspecific T-cell activation.

FIG. 10 shows IFNγ expression as a proxy for T cell response when cancercells were treated with controls or different concentrations ofconstructs, with very low levels with constructs having only a VH or VLfor the anti-CDE3 scFv, but positive control bispecific constructs (both9332 and 9333) showed higher levels of activity.

FIG. 11 provides a stoichiometric assessment of complementary constructsof a two-component system.

FIG. 12 shows IFNγ expression as a proxy for T cell response when MCF-7cancer cells were treated with controls or different concentrations ofconstructs.

FIG. 13 shows IFNγ expression as a proxy for T cell response when cancercells were treated with controls or different concentrations ofconstructs targeting EpCAM.

FIG. 14 shows IFNγ expression as a proxy for T cell response when cancercells were treated with controls or different concentrations ofconstructs targeting either biparatopic EGFR epitopes or a combinationof EpCAM and EGFR targeting.

FIG. 15 shows the impact of protease inhibitors on constructs eithercontaining protease cleavage sites or not containing protease cleavagesites.

FIG. 16 shows that different types of targeting moieties may be used, bysuccessfully pairing a construct having a VHH targeting moiety with aconstruct having an scFv moiety.

FIG. 17 shows a sequence schematic for constructs 6248 and 6249 with thevarious linkers boxed and the protease cleavage site in bold andunderline. The His tag is also in bold.

DESCRIPTION OF THE SEQUENCES

Tables 1A and 1B provide a listing of certain sequences referencedherein.

TABLE 1A Description of the Sequences and SEQ ID NOs DescriptionSequence # ADAM28 cleavage site KPAKFFRL   1 ADAM28 cleavage siteDPAKFFRL   2 ADAM28 cleavage site KPMKFFRL   3 ADAM28 cleavage siteLPAKFFRL   4 ADAM28 cleavage site LPMKFFRL   5 ADAM28 cleavage siteKPAMFFRL   6 ADAM28 cleavage site YPAKFFRL   7 ADAM28 cleavage siteKWAKFFRL   8 ADAM28 cleavage site DPMKFFRL   9 ADAM28 cleavage siteDPAMFFRL  10 ADAM28 cleavage site DPMMFFRL  11 ADAM28 cleavage siteKMAMFFRL  12 ADAM28 cleavage site KMAMFFIM  13 ADAM28 cleavage siteKPAMFFIM  14 ADAM28 cleavage site LPAMFFRL  15 ADAM28 cleavage siteLPMMFFRL  16 ADAM28 cleavage site LMAMFFRL  17 ADAM28 cleavage siteLMAMFFIM  18 ADAM28 cleavage site LPAMFFIM  19 ADAM28 cleavage siteLPAMFFYM  20 ADAM28 cleavage site KPMMFFRL  21 ADAM28 cleavage siteKPAKFFYM  22 ADAM28 cleavage site KPAKFFIM  23 ADAM28 cleavage siteIPMKFFRL  24 ADAM28 cleavage site IPAMFFRL  25 ADAM28 cleavage siteIPMMFFRL  26 ADAM28 cleavage site IMAMFFRL  27 ADAM28 cleavage siteIMAMFFIM  28 ADAM28 cleavage site IPAMFFIM  29 ADAM28 cleavage siteIPAMFFYM  30 cathepsin B cleavage site FR  31 cathepsin B cleavage siteFK  32 cathepsin B cleavage site VA  33 cathepsin B cleavage site VR  34cathepsin B cleavage site V{Cit}  35 cathepsin B cleavage site HLVEALYL 36 cathepsin B cleavage site SLLKSRMVPNFN  37 cathepsin B cleavage siteSLLIARRMPNFN  38 cathepsin B cleavage site KKFA  39cathepsin B cleavage site AFKK  40 cathepsin B cleavage site QQQ  41cathepsin D cleavage site PRSFFRLGK  42 cathepsin D cleavage siteSGVVIATVIVIT  43 cathepsin K cleavage site GGP  44 MMP1 cleavage siteSLGPQGIWGQFN  45 MMP2 cleavage site AIPVSLR  46 MMP2 cleavage siteSLPLGLWAPNFN  47 MMP2 cleavage site HPVGLLAR  48 MMP2 cleavage siteGPLGVRGK  49 MMP2 cleavage site GPLGLWAQ  50 MMP3 cleavage site STAVIVSA 51 MMP7 cleavage site GPLGLARK  52 MMP7 cleavage site RPLALWRS  53MMP7 cleavage site SLRPLALWRSFN  54 MMP2/9 cleavage site GILGVP  55MMP2/9 cleavage site GPLGIAGQ  56 MMP9 cleavage site AVRWLLTA  57MMP9 cleavage site PLGLYAL  58 MMP9 cleavage site GPQGIAGQR  59MMP9 cleavage site KPVSLSYR  60 MMP11 cleavage site AAATSIAM  61MMP11 cleavage site AAGAMFLE  62 MMP13 cleavage site GPQGLAGQRGIV  63MMP14 cleavage site PRHLR  64 MMP14 cleavage site PQGLLGAPGILG  65MMP14 cleavage site PRSAKELR  66 PSA/KLK3 HSSKLQ  67 PSA/KLK3 SSKLQ  68KLK4 RQQR  69 TMPRSS2 GGR  70 Legumain AAN  71 ST14 (Matriptase) QAR  72C1s cleavage site YLGRSYKV  73 C1s cleavage site MQLGRX  74MASP2 cleavage site SLGRKIQI  75 C2a and Bb cleavage site GLARSNLDE  76uPa cleavage site TYSRSRYL  77 uPa cleavage site KKSPGRVVGGSV  78uPa cleavage site NSGRAVTY  79 uPa cleavage site AFK  80tissue-type plasminogen activator GGSGQRGRKALE  81 (tPA) ADAM10PRYEAYKMGK  82 ADAM12 LAQAF  83 ADAM17 EHADLLAVVAK  84flexible amino acid linker (may be GGGGS  85presented in repeating fashion) flexible amino acid linker (may be GGGS 86 presented in repeating fashion)   flexible amino acid linker (may beGS  87 presented in repeating fashion)flexible amino acid linker (may be GSGGS  88presented in repeating fashion) flexible amino acid linker (may be GGSG 89 presented in repeating fashion) flexible amino acid linker (may beGGSGG  90 presented in repeating fashion)flexible amino acid linker (may be GSGSG  91presented in repeating fashion) flexible amino acid linker (may be GSGGG 92 presented in repeating fashion) flexible amino acid linker (may beGGGSG  93 presented in repeating fashion)flexible amino acid linker (may be GSSSG  94presented in repeating fashion) Anti-EGFR aptamer (tight binderUGCCGCUAUAAUGCACGGAUUUAAUC  95 with K_(d) = 2.4 nM)GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGGCGCUAAAUAGCACGGAAAUAAUC 96 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCUAGUAUAUCGCACGGAUUUAAUC  97 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCCGCCAUAUCACACGGAUUUAAUC  98GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UUCCGCUGUAUAACACGGACUUAAUC 99 GCCGUAGUAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGUCGCUCUAUUGCACGGAUUUAAUC 100 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCUGCUUUAUCCCACAUAUUUUUUC 101CCCUCAUAACAAUAUUUCUCCCCCC Anti-EGFR aptamer UGCNGCUAUAUCGCNCGUAUUUAAUC102 GCCGUAGAAAAGCAUGUCNANGCCG Anti-EGFR aptamerUGCAAAGAAAACGCACGUAUUUAAUC 103 GCCGUAGUAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCAUCACUAUCGAACCUAUUUAAUC 104CACCAAAAUAAUUGCAAGUCCAUACU C Anti-EGFR aptamerUGCCNNAAUAACACACNUAUAUAAUC 105 GCCGUACAAAAUCAUGUCAAANCCGAnti-EGFR aptamer UGCAGCUGUAUUGCACGUAUUUAAUC 106GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UUCCGAUAAUCCCGCGUACUAAAUCA107 CCAUAGUCAACAAUUUCCAACCUC Anti-EGFR aptamerUCCACUAUAUCACACGUAUUUAAUCG 108 CCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UCCCUCAACCUCGCUACUAUUUAAUC 109GCCGUAGAAAAGCAUGUCAAAGCCU Anti-EGFR aptamer UGCCGCUAUAUCACACGAAUUUAAUC110 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerAGCCCCUAGAACACACGGAUUUAAUC 111 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCCAAUAUAUAACACGGAAUUAAUC 112GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGCCGCUAUAGCGCACGGAUUUAAUC113 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCAGAUAUAUGUCACUCAUUAAUCC 114 CCGUAUAAAAACAUAACUAAGCUCAnti-EGFR aptamer UGUAGCUGUAUUGCACACAUUAAAUC 115GCCGUAGUAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UACCAAUAUAUCGCCACACAUAAUCG116 CCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCCGCUAUGCCCACGGAAUUUAAUC 117 GCCGUAGAAAAACAUGUCAAAGUCGAnti-EGFR aptamer UGCCGCUAUUUAGCACGGAUUAAAUC 118GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGCCGCUAUUUAGCACGGAUUAAAUC119 GCCGUAGAAAAGCAUGUCNAAGCCG Anti-EGFR aptamerUGUAGUAAUAUGACACGGAUUUAAUC 120 GCCGUAGAAAAGCANGUCAAAGCCUAnti-EGFR aptamer UGUCGCCAUUACGCACGGAUUUAAUC 121GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGCCCCCAAACUACACAAAUUUAAUC122 GCCGUAUAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCACUAUCUCACACGUACUAAUCGC 123 CGUAUAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGUCGCAAUAAUACACUAAUUUAAUC 124 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCAACAAUAUAGCACGUAUUUAAUC 125 GCCGUAGUAAAGCAUGUCAAAGGAnti-EGFR aptamer CUACCACAAAUCCCACAUAUUUAAUC 126UCCCAAUCAAAUCUUGUCCAUUCCC Anti-EGFR aptamer UGCCCUAAACUCACACGGAUAUAAUC127 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUUGUCGUAUGUCACACGUAUUAAAUC 128 GCCGUAUAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UUCCGCUAUAACACACGGAGAAAAUC 129GCCGUAGUAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGCCGAUAUAACGCACGGAUAUAAUC130 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCCAUUAUACAGCACGGAUUUAAUC 131 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UCCAGAAAUAUGCACACAUUUAAUCG 132CCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UCCGCUAAACAACACGGAUACAAUCG133 CCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGCACUAUCUCACACGUACUAAUCGC 134 CGUAUAAAAGCAUGUCAAANNNG Anti-EGFR aptamerAUNGCNANNNUACACGUAUUNAAUCG 135 CCGUAGAAAAGCAUGUCANAGCCGAnti-EGFR aptamer UGCUGCUAUAUUGCAAUUUUUUAAAC 136UAAGUAGAAAACCAUGUACAAGUCG Anti-EGFR aptamer UGUCGCCAUAUUGCACGGAUUUAAUC137 GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGCCGUUAUAACCCACGGAAUUUAAC 138 CUCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGUGAAUAUAUAUCACGGAUUUAAUC 139GCCGUAUAAAAGCNAUGUCAAAGCCG Anti-EGFR aptamer UGCCGAUAUNNANCACGGAUUUAAUC140 GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGUCACUAAAUUGCACGUAUAUAAUC 141 GCCGUAGUAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCAACCAUAAAGCACGUAAUAAAUC 142GCCGUAUAUAAGCAUGUCaAAGCCG Anti-EGFR aptamer UGCCGCUAUAUAGCACGUAUUAAUCG143 CCGUAGUAAAGCAUGUCaAAGCCG Anti-EGFR aptamerUGCCGCUAUAGCACACGGAAUUUAAU 144 CGCCGUAGUAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCAGGUAUAUAACNCGGAUUUAAUC 145GCCGUAGAAAAGCAUGUCNAAGCCG Anti-EGFR aptamer UGCUCCUAUAACACACGGAUUUAAUC146 GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGCCCGUAAUUGCACGGAUUUAAUCG 147 CCGUAGAAAAGCAUGUCCAAGCCGGAnti-EGFR aptamer ACUCCCUAUAUNGCAACUACAUAAUC 148GCCGUAAAUAAGCAUGUNCAAGCCG Anti-EGFR aptamer UGAAGCUAGAUCACACUAAAUUAAUC149 GCCGUAGAAAAGCAUGUCAAAAAAGC CG Anti-EGFR aptamerUGACUCUUUAUCCCCCGUACAUUAUU 150 cACCGACCAAAGCAUUACCAUCCCCAnti-EGFR aptamer UGACGCCCUAACACACGUAUAUAAUC 151GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamer UGUCGCAAAAUAGCACGUAUUUAAUC152 GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGAGUGUAUAAUUCACGUAUUUAAUC 153 GCCGUAGAAAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCUACUAUAUCGUAGGUAACUAAUC 154GCCCUACAAACUCACUCUAAAACCG Anti-EGFR aptamer UUACGCUAUAUCACACGGAAUUUUAA155 UCGCCGUAGAAAAGCAUGUCCAAGCC G Anti-EGFR aptamerCCCAUCUGUACUACAGGAAUUUAAUC 156 GCCGUAGAAAAGCAUGUCCAAGCCGAnti-EGFR aptamer UGCCCAUAAAUAGCACGGAUUUAAUC 157GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamer UGCCGCAAUAACAUACACAUAUAAUC158 GCCGUAGAAAAGCAUGUCAAAGCCG Anti-EGFR aptamerUGCAACUAUAUCGCACGUAUGUAAUC 159 GCCGUAGAAAAAGCAUGUCAAAGCCAnti-EGFR aptamer UUCCGCUAUAUAGCACGGAAUUAAUC 160GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamer UUCCGCUAAGUCACACGAAAUUAAUC161 GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamerUGUAGCAAUAUCACACGUAAUUAAUC 162 GCCGUAUAUAAGCAUGUCAAAGCCGAnti-EGFR aptamer UGCCGUUAUAUAUCACGGAUUUAAUC 163GCCGUAGAAAAGCAUGUCCAAGCCG Anti-EGFR aptamer UAACACAUAUAUCAAGUAACUUAUCU164 CCUUAGUAACCAUCUCCAAGCCG HLA-A*0201-restricted viral NLVPMVATV 178peptide

TABLE 1B Description of Construct Sequences and SEQ ID NOs DescriptionSequence # Construct 6254 ELVMTQSPSSLTVTAGEKVTMSCKSS 165single chain; scFv anti-EPCAM QSLLNSGNQKNYLTWYQQKPGQPPKL[Mus musculus V-KAPPA LIYWASTRESGVPDRFTGSGSGTDFT (IGKV8-19*01LTISSVQAEDLAVYYCQNDYSYLPTF (98.00%)-IGK]5*01 L126 > I (112))GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9] (1-113)-15-merQLLEQSGAELVRPGTSVKISCKASGY tris(tetraglycyl-seryl) linker (114-AFTNYWLGWVKQRPGHGLEWIGDIFP 128)-Mus musculus VH (IGHV1-GSGNIHYNEKFKGKATLTADKSSSTA 54*01 (85.90%)-(IGHD)-YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 > T (243)) [8.8.14]MDYWGQGTTVTVSSGGGGSGVQLVQS (129-248)]-5-mer tetraglycyl-serylGAEVKKPGASVKVSCKASGYTFTRYT linker (249-253)-scFv anti-CD3EMHWVRQAPGQGLEWIGYINPSRGYTN [humanized VH (Homo sapiensYADSVKGRFTITTDKSTSTAYMELSS IGHV1-46*01 (82.50%)-(IGHD)-LRSEDTATYYCARYYDDHYCLDYWGQ IGHJ6*01) [8.8.12] (254-372)-18-GTTVTVSSGEGTSTGSGGSGGSGGAD mer linker (373-390)-V-KAPPADIVLTQSPATLSLSPGERATLSCRAS (Mus musculus IGKV4-59*01QSVSYMNWYQQKPGKAPKRWIYDTSK (81.70%-IGKJ1*01 L124 > V (493)VASGVPARFSGSGSGTDYSLTINSLE [5.3.9] (391-496)] hexahistidineAEDAATYYCQQWSSNPLTFGGGTKVE (497-502) IKHHHHHHCAS Registry Number 1005198-65-1 ChemID: 1005198-65-1 Construct 6246ELVMTQSPSSLTVTAGEKVTMSCKSS 166 single chain; scFv anti-EPCAMQSLLNSGNQKNYLTWYQQKPGQPPKL [Mus musculus V-KAPPALIYWASTRESGVPDRFTGSGSGTDFT (IGKV8-19*01 LTISSVQAEDLAVYYCQNDYSYPLTF(98.00%)-IGK]5*01 L126 > I (112)) GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9](1-113)-15-mer QLLEQSGAELVRPGTSVKISCKASGYtris(tetraglycyl-seryl) linker (114- AFTNYWLGWVKQRPGHGLEWIGDIFP128)-Mus musculus VH (IGHV1- GSGNIHYNEKFKGKATLTADKSSSTA54*01 (85.90%)-(IGHD)- YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 >T (243)) [8.8.14] MDYWGQGTTVTVSSGGGGSDVQLVQS(129-248)]-5-mer tetraglycyl-seryl GAEVKKPGASVKVSCKASGYTFTRYTlinker (249-253)-scFv anti-CD3E MHWVRQAPGQGLEWIGYINPSRGYTN[humanized VH (Homo sapiens YADSVKGRFTITTDKSTSTAYMELSSIGHV1-46*01 (82.50%)-(IGHD)- LRSEDTATYYCARYYDDHYCLDYWGQIGHJ6*01) [8.8.12] (254-372)-18- GTTVTVSSGEGTSTGSGGSGGSGGADmer linker (373-390)-hexahistidine HHHHHH (391-396) Construct 6247ELVMTQSPSSLTVTAGEKVTMSCKSS 167 single chain; scFv anti-EPCAMQSLLNSGNQKNYLTWYQQKPGQPPKL [Mus musculus V-KAPPALIYWASTRESGVPDRFTGSGSGTDFT (IGKV8-19*01 LTISSVQAEDLAVYYCQNDYSYPLTF(98.00%)-IGK]5*01 L126 > I (112)) GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9](1-113)-15-mer QLLEQSGAELVRPGTSVKISCKASGYtris(tetraglycyl-seryl) linker (114- AFTNYWLGWVKQRPGHGLEWIGDIFP128)-Mus musculus VH (IGHV1- GSGNIHYNEKFKGKATLTADKSSSTA54*01 (85.90%)-(IGHD)- YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 >T (243)) [8.8.14] MDYWGQGTTVTVSSGGGGSDIVLTQS(129-248)]-5-mer tetraglycyl-seryl PATLSLSPGERATLSCRASQSVSYMNlinker (249-253)-anti-CD3E-V- WYQQKPGKAPKRWIYDTSKVASGVPAKAPPA (Mus musculus IGKV4- RFSGSGSGTDYSLTINSLEAEDAATY59*01 (81.70%)-IGKJ1*01 L124 > V YCQQWSSNPLTFGGGTKVEIKHHHHH (356) H[5.3.9] (254-359)]-hexahistidine (360-365) Construct 6248ELVMTQSPSSLTVTAGEKVTMSCKSS 168 single chain; scFv anti-EPCAMQSLLNSGNQKNYLTWYQQKPGQPPKL [Mus musculus V-KAPPALIYWASTREAGVPDRFTGSGSGTDFT (IGKV8-19*01 LTISSVQAEDLAVYYCQNDYSYPLTF(98.00%)-IGK]5*01 L126 > I (112)) GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9](1-113)-15-mer QLLEQSGAELVRPGTSVKISCKASGYtris(tetraglycyl-seryl) linker (114- AFTNYWLGWVKQRPGHGLEWIGDIFP128)-Mus musculus VH (IGHV1- GSGNIHYNEKFKGKATLTADKSSSTA54*01 (85.90%)-(IGHD)- YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 >T (243)) [8.8.14] MDYWGQGTTVTVSSGGGGSDVQLVQS(129-248)]-5-mer tetraglycyl-seryl GAEVKKPGASVKVSCKASGYTFTRYTlinker (249-253)-anti-CD3E MHWVRQAPGQLGEWIGYINPSRGYTN[humanized VH (Homo sapiens YADSVKGRFTITTDKSTSTAYMELSSIGHV1-46*01 (82.50%)-(IGHD)- LRSEDTATYYCARYYDDHYCLDYWGQIGHJ6*01) [8.8.12] (254-372)-25- GTTVTVSSGEGTSTGSGAIPVSLRGSmer linker (373-397) containing GGSGGADDIVLTQSPATLSLSPGERAMMP2 cleavage site AIPVSLR TLSCRASQSVSSSYLAWYQQKPGQAP(SEQ ID NO: 46))-V-KAPPA RLLIYGASSRATGVPARFSGSGSGTD(Homo sapiens V-KAPPA from FTLTISSLEPEDFATYYCLQIYNMPIgantenerumab, CAS: 1043556-46-2; TFGQGTKVEIKHHHHHH398-505); 86-hexahistidine (506-511) Construct 6249ELVMTQSPSSLTVTAGEKVTMSCKSS 169 single chain; scFv anti-EPCAMQSLLNSGNQKNYLTWYQQKPGQPPKL [Mus musculus V-KAPPALIYWASTRESGVPDRFTGSGSGTDFT (IGKV8-19*01 LTISSVQAEDLAVYYCQNDYSYPLTF(98.00%)-IGK]5*01 L126 > I (112)) GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9](1-113)-15-mer QLLEQSGAELVRPGTSVKISCKASGYtris(tetraglycyl-seryl) linker (114- AFTNYWLGWVKQRPGHGLEWIGDIFP128)-Mus musculus VH (IGHV1- GSGNIHYNEKFKGKATLTADKSSSTA54*01 (85.90%)-(IGHD)- YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 >T (243)) [8.8.14] MDYWGQGTTVTVSSGGGGSDIVLTQS(129-248)]-5-mer tetraglycyl-seryl PATLSLSPGERATLSCRASQSVSYMNlinker (249-253)-scFv anti-CD3E WYQQKPGKAPKRWIYDTSKVASGVPAV-KAPPA (Mus musculus IGKV4- RFSGSGSGTDYSLTINSLEAEDAATY59*01 (81.70%-IGKJ1*01 L124 > V YCQQWSSNPLTFGGGTKVEIKGEGTS (493)[5.3.9](254-359)]- TGSGAIPVSLRGSGGSGGADDVQLVQ 25-mer-linker (360-384 containingSGAEVKKPGASVKVSCKASGYTFTGY MMP2 cleavage site AIPVSLRYMHWVRQAPGQGLEWMGWINPNSGGT (SEQ ID NO: 46))-Ig heavy chainNYAQKFQGRVTITRDTSASTAYMELS V region (clone alpha-MUC1-1,SLRSEDTAVYYCARDFLSGYLDYWGQ GenGank Accession S36265; 385-502)-GTLVTVSSHHHHHH hexahistidine (503-508) Construct 9327ELVMTQSPSSLTVTAGEKVTMSCKSS 170 EpCAM V_(L)V_(H)-V_(H)DV_(L)QSLLNSGNQKNYLTWYQQKPGQPPKL single chain; scFv anti-EPCAMLIYWASTRESGVPDRFTGSGSGTDFT [Mus musculus V-KAPPALTISSVQAEDLAVYYCQNDYSYPLTF (IGKV8-19*01 GAGTKLEIKGGGGSGGGGSGGGGSEV(98.00%)-IGK]5*01 L126 > I (112)) QLLEQSGAELVRPGTSVKISCKASGY [12.3.9](1-113)-15-mer AFTNYWLGWVKQRPGHGLEWIGDIFPtris(tetraglycyl-seryl) linker (114- GSGNIHYNEKFKGKATLTADKSSSTA128)-Mus musculus VH (IGHV1- YMQLSSLTFEDSAVYFCARLRNWDEP54*01 (85.90%)-(IGHD)- MDYWGQGTTVTVSSGGGGSDVQLVQS IGHJ4*01, S123 >T (243)) [8.8.14] GAEVKKPGASVKVSCKASGYTFTRYT(129-248)]-5-mer tetraglycyl-seryl MHWVRQAPGQGLEWIGYINPSRGYTNlinker (249-253)-scFv anti-CD3E YADSVKGRFTITTDKSTSTAYMELSS[humanized VH (Homo sapiens LRSEDTATYYCARYYDDHYCLDYWGQIGHV1-46*01 (82.50%)-(IGHD)- GTTVTVSSGEGTSTGSGGGGSGGGGSIGHJ6*01) [8.8.12] (254-372)-25- GGSGGADDIVLTQSPATLSLSPGERAmer linker (373-397)-V-KAPPA TLSCRASQSVSSSYLAWYQQKPGQAP(Homo sapiens V-KAPPA from RLLIYGASSRATGVPARFSGSGSGTDgantenerumab, CAS: 1043556-46-2; FTLTISSLEPEDFATYYCLQIYNMPI398-505); 86-hexahistidine TFGQGTKVEIKHHHHHH (506-511)Anti-EpCAM sequence from Brischwein K et al, Mol. Immunol.(2006) 43: 1129-43 Construct 9328 ELVMTQSPSSLTVTAGEKVTMSCKSS 171single chain; scFv anti-EPCAM QSLLNSGNQKNYLTWYQQKPGQPPKL[Mus musculus V-KAPPA LIYWASTRESGVPDRFTGSGSGTDFT (IGKV8-19*01LTISSVQAEDLAVYYCQNDYSYPLTF (98.00%)-IGK]5*01 L126 > I (112))GAGTKLEIKGGGGSGGGGSGGGGSEV [12.3.9] (1-113)-15-merQLLEQSGAELVRPGTSVKISCKASGY tris(tetraglycyl-seryl) linker (114-AFTNYWLGWVKQRPGHGLEWIGDIFP 128)-Mus musculus VH (IGHV1-GSGNIHYNEKFKGKATLTADKSSSTA 54*01 (85.90%)-(IGHD)-YMQLSSLTFEDSAVYFCARLRNWDEP IGHJ4*01, S123 > T (243)) [8.8.14]MDYWGQGTTVTVSSGGGGSDIVLTQS (129-248)]-5-mer tetraglycyl-serylPATLSLSPGERATLSCRASQSVSYMN linker (249-253)-scFv anti-CD3EWYQQKPGKAPKRWIYDTSKVASGVPA V-KAPPA (Mus musculus IGKV4-RFSGSGSGTDYSLTINSLEAEDAATY 59*01 (81.70%-IGKJ1*01 L124 > VYCQQWSSNPLTFGGGTKVEIKGEGTS (493)[5.3.9] (254-359)]-25-merTGSGGGGSGGGGSGGSGGADDVQLVQ linker (360-384)-Ig heavy chain VSGAEVKKPGASVKVSCKASGYTFTGY region (clone alpha-MUC1-1,YMHWVRQAPGQGLEWMGWINPNSGGT GenBank Accession S36265; 385-NYAQKFQGRVTITRDTSASTAYMELS 502)-hexahistidine (503-508)SLRSEDTAVYYCARDFLSGYLDYWGQ GTLVTVSSHHHHHH Construct 9329QVQLVQSGGGLVQPGGSLRLSCAASY 172 Glypican3 V_(HH)-CD3ϵ(V_(H)-MMP2-V_(L))FDFSDYEMSWVRQAPGKGLEWIGSIY Anti-human Glypican-3 VHHHSGSTYYNPSLKSRVTISRDNSKNTL sequence from U.S. Pat. No.YLQMNTLRAEDTATYYCARVNMDRFD 2012145469; residues 1-116)-5-merYWGQTLTVTVSSSGGGGSDVQLVQSG tris(tetraglycyl-seryl) linkerAEVKKPGASVKVSCKASGYTFTRYTM (117-122)-scFv anti-CD3EHWVRQAPGQGLEWIGYINPSRGYTNY [humanized VH (Homo sapiensADSVKGRFTITTDKSTSTAYMELSSL IGHV1-46*01 (82.50%)-(IGHD)-RSEDTATYYCARYYDDHYCLDYWGQG IGHJ6*01 [8.8.12] (123-241)-25-TTVTVSSGEGTSTGSGAIPVSLRGSG mer linker (242-266 containingGSGGADDIVLTQSPATLSLSPGETAT MMP2 cleavage site AIPVSLRLSCRASQSVSSSYLAWYQQKPGQAPR (SEQ ID NO: 46))-V-KAPPALLIYGASSRATGVPARFSGSGSGTDF (Homo sapiens V-KAPPA fromTLTISSLEPEDFATYYCLQIYNMPIT gantenerumab, CAS: 1043556-46-2;FGQGTKVEIKHHHHHH 267-374); -hexahistidine (375-380) Construct 9330DIQMTQSTSSLSASLGDRVTISCSAS 173 anti-[Homo sapiens SDC1QGINNYLNWYQQKPDGTVELLIYYTS (syndecan-1, CD138), scFv, fromTLQSGVPSRFSGSGSGTDYSLTISNL indatuximab CAS: 1238517-16-2,EPEDIGTYYCQQYSKLPRTFGGGTKL U.S. Pat. No. US20140010828], [MusEIKRGGGGSGGGGSGGGGSQVQLQQS musculus V-KAPPA (IGKV10-GSELMMPGASVKISCKATGYTFSNYW 94*01-IGKJ1*01) [6.3.9] (1-108)-IEWVKQRPGHGLEWIGEILPGRGRTI 15-mer tris(tetraglycyl-seryl)YNEKFKGKATFTADISSNTVQMQLSS linker (109-123) [Mus musculus VHLTSEDSAVYYCARRDYYGNFYYAMDY (IGHV1-9*01-(IGHD)-WGQGTSVTVSSGGGGSDVQLVQSGAE IGHJ6*01 [8.8.15] (124-245)-5-VKKPGASVKVSCKASGYTFTRYTMHW mer tris(tetraglycyl-seryl) linkerVRQAPGQGLEWIGYINPSRGYTNYAD (246-250)-scFv anti-CD3ESVKGRFTITTDKSTSTAYMELSSLRS [humanized VH (Homo sapiensEDTATYYCARYYDDHYCLDYWGQGTT IGHV1-46*01 (82.50%)-(IGHD)-VTVSSGEGTSTGSGAIPVSLRGSGGS IGHJ6*01 [8.8.12] (251-369)-25-GGADDIVLTQSPATLSLSPGERATLS mer linker (370-394 containingCRASQSVSSSYLAWYQQKPGQAPRLL MMP2 cleavage site AIPVSLRIYGASSRATGVPARFSGSGSGTDFTL (SEQ ID NO: 46))-V-KAPPATISSLEPEDFATYYCLQIYNMPITFG (Homo sapiens V-KAPPA from QGTKVEIKHHHHHHgantenerumab, CAS: 1043556-46-2; 395-502); -hexahistidine (503-508)Construct 9332 QVKLEESGGGSVQTGGSLRLTCAASG 174EGFR V_(HH)-CD3ϵ(V_(H)-V_(L)) RTSRSYGMSWFRQAPGKEREFVSGISAnti-human EGFR V_(HH) sequence WRGDSTGYADSVKGRFTISRDNAKNTfrom 7D12 sequence from Schmitz VDLQMNSLKPEDTAIYYCAAAAGSAWKR et al, Structure. 2013 Jul. YGTLYEYDYWGQGTQVTVSSGGGGSG2; 21(7): 1214-24; residues 1-124)- GGGSGGGGSGGGGSGGGGSGGGGSDV30-mer tris(tetraglycyl-seryl) QLVQSGAEVKKPGASVKVSCKASGYTlinker (125-154)-scFv anti-CD3E FTRYTMHWVRQAPGQGLEWIGYINPS[humanized VH (Homo sapiens RGYTNYADSVKGRFTITTDKSTSTAYIGHV1-46*01 (82.50%)-(IGHD)- MELSSLRSEDTATYYCARYYDDHYCLIGHJ6*01) [8.8.12] (155-273)-18- DYWGQGTTVTVSSGEGTSTGSGGSGGmer linker (274-291)-V-KAPPA SGGADDIVLTQSPATLSLSPGERATL(Mus musculus IGKV4-59*01 SCRASQSVSYMNWYQQKPGKAPKRWI(81.70%)-IGKJ1*01 L124 > V (394) YDTSKVASGVPARFSGSGSGTDYSLT [5.3.9](292-397)-hexahistidine INSLEAEDAATYYCQQWSSNPLTFGG (398-403)GTKVEIKHHHHHH Anti-human CD3ϵ sequence fromBrischwein K et al, Mol. Immunol. (2006) 43: 1129-43U.S. Pat. No. US7919089 Construct 9332 EVQLVESGGGLVQAGGSLRLSCAASG 175EGFR V_(HH)-CD3ϵ(V_(H)-V_(L)) RTFSSYAMGWFRQAPGKEREFVVAINAnti-human EGFR V_(HH) sequence WSSGSTYYADSVKGRFTISRDNAKNTfrom 9G8 sequence from Schmitz MYLQMNSLKPEDTAVYYCAAGYQINSKR et al, Structure. 2013 Jul. GNYNFKDYEYDYWGQGTQVTVSSGGG2; 21(7): 1214-24; residues 1-127)- GSGGGGSGGGGSGGGGSGGGGSGGGG30-mer tris(tetraglycyl-seryl) SDVQLVQSGAEVKKPGASVKVSCKASlinker (128-157)-scFv anti-CD3E GYFTFRYTMHWVRQAPGQGLEWIGYI[humanized VH (Homo sapiens NPSRGYTNYADSVKGRFTITTDKSTSIGHV1-46*01 (82.50%)-(IGHD)- TAYMELSSLRSEDTATYYCARYYDDHIGHJ6*01) [8.8.12] (158-276)-18- YCLDYWGQGTTVTVSSGEGTSTGSGGmer linker (277-294)-V-KAPPA SGGSGGADDIVLTQSPATLSLSPGER(Mus musculus IGKV4-59*01 ATLSCRASQSVSYMNWYQQKPGKAPK(81.70%)-IGKJ1*01 L124 > V (394) RWIYDTSKVASGVPARFSGSGSGTDY [5.3.9](292-397)-hexahistidine SLTINSLEAEDAATYYCQQWSSNPLT (401-406)FGGGTKVEIKHHHHHH Construct 9334 QVKLEESGGGSVQTGGSLRLTCAASG 176EGFR V_(HH)-CD3ϵ(V_(H)-MMP2-V_(L)) RTSRSYGMGWFRQAPGKEREFVSGISAnti-human EGFR V_(HH) sequence WRGDSTGYADSVKGRFTISRDNAKNTfrom 7D12 sequence from Schmitz VDLQMNSLKPEDTAIYYCAAAAGSAWKR et al, Structure. 2013 Jul. YGTLYEYDYWGQGTQVTVSSGGGGSG2; 21(7): 1214-24; residues 1-124)- GGGSGGGGSGGGGSGGGGSGGGGSDV30-mer tris(tetraglycyl-seryl) QLVQSGAEVKKPASSVKVSCKASGYTlinker (125-154)-scFv anti-CD3E FTRYTMHWVRQAPGQGLEWIGYINPS[humanized VH (Homo sapiens RGYTNYADSVKGRFTITTDKSTSTAYIGHV1-46*01 (82.50%)-(IGHD)- MELSSLRSEDTATYYCARYYDDHYCLIGHJ6*01) [8.8.12] (155-273)-25- DYWGQGTTVTVSSGEGTSTGSGAIPVmer linker (274-298) containing SLRGSGGSGGADDIVLTQSPATLSLSMMP2 cleavage site AIPVSLR PGERATLSCRASQSVSSSYLAWYQQK(SEQ ID NO: 46))-V-KAPPA PGQAPRLLIYGASSRATGVPARFSGS(Homo sapiens V-KAPPA from GSGTDFTLTISSLEPEDFATYYCLQIgantenerumab, CAS: 1043556-46-2; YNMPITFGQGTKVEIKHHHHHH299-406); -hexahistidiine (407-412) Construct 9335WSSGSTYYADSVKGRFTISRDNAKNT 177 EGFR V_(HH)-CD3ϵ(V_(L)-MMP2-V_(H))MYLQMNSLKPEDTAVYYCAAGYQINS Anti-human EGFR V_(HH) sequenceGNYNFKDYEYDYWGQGTQVTVSSGGG from 9G8 sequence from SchmitzGSGGGGSGGGGSGGGGSGGGGSGGGG KR et al, Structure. 2013 Jul.SDIVLTQSPATLSLSPGERATLSCRA 2; 21(7): 1214-24; residues 1-127)-SQSVSYMNWYQQKPGKAPKRWIYDTS 30-mer tris(tetraglycyl-seryl)KVASGVPARFSGSGSGTDYSLTINSL linker (128-157)-scFv anti-CD3EEAEDAATYYCQQWSSNPLTFGGGTKV V-KAPPA (Mus musculus IGKV4-EIKGEGTSTGSGAIPVSLRGSGGSGG 59*01 (81.70%)-IGKJ1*01 L124 > VADDVQLVQSGAEVKKPGASVKVSCKA (493)[5.3.9] (158-263)]-25-merSGYTFTGYYMHWVRQAPGQGLEWMGW linker (264-288 containing MMP2INPNSGGTNYAQKFQGRVTITRDTSA cleavage site AIPVSLR (SEQ ID NO:STAYMELSSLRSEDTAVYYCARDFLS 46))-Ig heavy chain V regionGYLDYWGQGTLVTVSSHHHHHH (clone alpha-MUC1-1, GenBankAccession S36265; 289-406)- hexahistidine (307-412)

DESCRIPTION OF THE EMBODIMENTS I. A Two-Component System Comprising atLeast One Targeted T-Cell Engaging Agent

A variety of targeted T-cell engaging agents are described in differentembodiments, and in some embodiment as part of a two-component systemcomprising a first component and a second component. In each of theembodiments, however, a targeting moiety may be used to deliver thetargeted T-cell engaging agent to an area of unwanted cells, allowingfor a therapeutic effect to be delivered locally. The targeted T-cellengaging agent also contains a first T-cell engaging domain capable ofactivity when binding a second T-cell engaging domain, but the secondT-cell engaging domain is not part of the targeted T-cell engagingagent. In other words, without the second T-cell engaging domain that isnot part of the targeted T-cell engaging agent, the first T-cellengaging domain is not capable of T-cell engaging activity. The targetedT-cell engaging agent also comprises an inert binding partner capable ofbinding the first T-cell engaging domain and preventing it from bindingto a second T-cell engaging domain. In other words, the inert bindingpartner binds to the first T-cell engaging domain such that the firstT-cell engaging domain does not bind to the second T-cell engagingdomain unless the inert binding partner is removed. By does not bind,the application does not exclude nonspecific binding or low levels ofbinding (for example, ≤1%, ≤5%, ≤10%). The concept is one of functionalinsufficiency with the de novo VH/VL complementation insufficient forT-cell target binding. Proteolytic cleavage liberates the inert VH or VLgroups allowing the opportunity for re-pairing of active VH and VL pairsat the cell surface. Furthermore, the targeted T-cell engaging agentincludes a cleavage site separating the first T-cell engaging domain andthe inert binding partner. The cleavage site is cleaved when thetargeted T-cell engaging agent is in the microenvironment of theunwanted cells.

In some embodiments, the second T-cell engaging domain is part of asecond targeted T-cell engaging agent. Thus, in some embodiments, a kitor composition may comprise two targeted T-cell engaging agents, onewith a first T-cell engaging domain and another with a second T-cellengaging domain. In such a kit or composition, the inert bindingpartners may be capable of dissociation once the cleavage site in eachagent has been cleaved; after dissociation, the two T-cell engagingdomains may be capable of binding to each other and exhibiting activity.

In some embodiments with two targeted T-cell engaging agents, thetwo-component system comprises one T-cell engaging domain that may be aVH domain and another T-cell engaging domain that may be a VL domain. Inembodiments with two targeted T-cell engaging agents, the targetingmoieties in the first component and the second component may be the sameor they may be different.

In embodiments with two targeted T-cell engaging agents, the cleavagesites in the first component and the second component may be the same orthey may be different.

FIG. 1 shows one embodiment of a targeted T-cell engaging agentconstruct comprising (a) an scFv targeting domain comprising a VH domainand a VL domain that bind the target, wherein the VH and VL domain areconnected by a flexible linker; (b) an inactive T-cell engaging domaincomprising a VL domain that binds to an inert VH domain, wherein the VHand VL domains are connected by a flexible linker having a cleavagesite, and (c) a flexible linker joining the targeting domain and theinactive T-cell engaging domain.

In some embodiments, FIG. 2 shows the process by which the cleavablelinker is cleaved and the inert binding partner is released to create anentity without an inert binding partner. This entity is still inactivebecause the VL domain in the T-cell engaging domain is not active on itsown.

In some embodiments, FIG. 3 illustrates the creation of an activetargeted T-cell engaging agent after the inert binding partner isreleased from a pair of complementary targeted T-cell engaging agents.

In some embodiments, FIGS. 4A-C illustrate the cleavage of the stepwiseprocess of the targeted T-cell engaging agents binding to the targetcell (4A), cleavage of the inert binding partners (4A and 4B), andbinding to create an active targeted T-cell engaging agent (4C).

In some alternative embodiments, the second T-cell engaging domain maynot be bound to a targeting moiety and/or may not comprise a cleavagesite and inert binding partner. In some instances, the second T-cellengaging domain may be conjugated or linked to a targeting moiety(either the same targeting moiety or a different targeting moiety), butin such an embodiment it would not be conjugated or linked to an inertbinding partner. In such an embodiment, only the first T-cell engagingdomain is bound to an inert binding partner. In another embodiment, thesecond T-cell engaging domain may also comprise a targeting moiety, acleavage site, and an inert binding partner, each as described herein.

In some embodiments, the structural arrangement from N-terminus toC-terminus of the first component comprises IBVL-L1-TCEVH-L2-TVL-L3-TVH.In some embodiments, the structural arrangement from N-terminus toC-terminus of the second component comprises TCEVL-L2-TVH-L3-TVL. Insome embodiments, the structural arrangement from N-terminus toC-terminus of the second component comprisesIBVH-L1-TCEVL-L2-TBVH-L3-TBVL. In each of these embodiments IB standsfor inert binding partner and IBVL is a VL inert binding partner,whereas IBVH is a VH insert binding domain. TCE stands for T-cellengaging and an TCEVL is a VL portion of a T-cell engaging domain and aTCEVH is a VH portion of a T-cell engaging domain TB stand for targetbinding domain and a TBVH is a VH portion of a target binding domain anda TBVL is a VL portion of a target binding domain. L1 is a linker with aprotease cleavage site, while L2 and L3 are optionally linkers thatoptionally are not cleavable by the same protease as L1.

A. Targeting Moiety

The targeting moiety functions in the targeted T-cell engaging agent bydelivering the agent to the local environment of the unwanted cells,enabling a localized treatment strategy. In certain embodiments, thetargeting moiety targets the unwanted cells by specifically binding tothe unwanted cells. In some instances, the targeting moiety specificallybinds the unwanted cells even while the inert binding partner is bindingthe first T-cell engaging domain.

In some embodiments, a first targeting moiety is bound, optionally by alinker, to a first T-cell engaging domain and, as part of a separateconstruct, a second targeting moiety is bound, optionally by a linker,to a second T-cell engaging domain. In this way, each complementary partof the T-cell engaging domain is delivered to the unwanted cells by aseparate targeting moiety. In some embodiments, the targeting moietiesare of the same type and, in some embodiments, the targeting moietiesare different. When the targeting moieties are of different types, theycan either target different epitopes (either overlapping ornonoverlapping) on the same target protein of the unwanted cell or theycan target different target proteins. In situations when the targetingmoieties target different proteins, the unwanted cell will express anantigen corresponding to each of the two types of targeting moieties,providing additional specificity for this approach.

In certain embodiments, the targeting moiety is an antibody orfunctional part thereof. By functional part, we mean any antibodyfragment that retains its binding activity to the target on the unwantedcell, such as an scFv or VHH or other functional fragment including animmunoglobulin devoid of light chains, Fab, Fab′, F(ab′)₂, Fv, antibodyfragment, diabody, scAB, single-domain heavy chain antibody,single-domain light chain antibody, Fd, CDR regions, or any portion orpeptide sequence of the antibody that is capable of binding antigen orepitope. Unless specifically noted as “full length antibody,” when theapplication refers to antibody it inherently includes a reference to afunctional part thereof.

Certain antibody targets (with examples of unwanted cell types inparentheses) may include: Her2/Neu (Epithelial malignancies); CD22 (Bcells, autoimmune or malignant); EpCAM (CD326) (Epithelialmalignancies); EGFR (epithelial malignancies); PSMA (ProstateCarcinoma); CD30 (B cell malignancies); CD20 (B cells, autoimmune,allergic or malignant); CD33 (Myeloid malignancies); membrane IgE(Allergic B cells); IgE Receptor (CD23) (Mast cells or B cells inallergic disease), CD80 (B cells, autoimmune, allergic or malignant);CD86 (B cells, autoimmune, allergic or malignant); CD2 (T cell or NKcell lymphomas); CA125 (multiple cancers including Ovarian carcinoma);Carbonic Anhydrase IX (multiple cancers including Renal Cell Carcinoma);CD70 (B cells, autoimmune, allergic or malignant); CD74 (B cells,autoimmune, allergic or malignant); CD56 (T cell or NK cell lymphomas);CD40 (B cells, autoimmune, allergic or malignant); CD19 (B cells,autoimmune, allergic or malignant); c-met/HGFR (Gastrointestinal tractand hepatic malignancies; TRAIL-R1 (multiple malignancies includingovarian and colorectal carcinoma); DRS (multiple malignancies includingovarian and colorectal carcinoma); PD-1 (B cells, autoimmune, allergicor malignant); PD-L1 (Multiple malignancies including epithelialadenocarcinoma); IGF-1R (Most malignancies including epithelialadenocarcinoma); VEGF-R2 (The vasculature associated with the majorityof malignancies including epithelial adenocarcinomas; Prostate stem cellantigen (PSCA) (Prostate Adenocarcinoma); MUC1 (Epithelialmalignancies); CanAg (tumors such as carcinomas of the colon andpancreas); Mesothelin (many tumors including mesothelioma and ovarianand pancreatic adenocarcinoma); P-cadherin (Epithelial malignancies,including breast adenocarcinoma); Myostatin (GDF8) (many tumorsincluding sarcoma and ovarian and pancreatic adenocarcinoma); Cripto(TDGF1) (Epithelial malignancies including colon, breast, lung, ovarian,and pancreatic cancers); ACVRL 1/ALK1 (multiple malignancies includingleukemias and lymphomas); MUC5AC (Epithelial malignancies, includingbreast adenocarcinoma); CEACAM (Epithelial malignancies, includingbreast adenocarcinoma); CD137 (B cells or T cells, autoimmune, allergicor malignant); CXCR4 (B cells or T cells, autoimmune, allergic ormalignant); Neuropilin 1 (Epithelial malignancies, including lungcancer); Glypicans (multiple cancers including liver, brain and breastcancers); HERS/EGFR (Epithelial malignancies); PDGFRa (Epithelialmalignancies); EphA2 (multiple cancers including neuroblastoma,melanoma, breast cancer, and small cell lung carcinoma); CD38 (Myeloma);CD138 (Myeloma); α4-integrin (AML, myeloma, CLL, and most lymphomas).

In certain modes, antibodies include an anti-epidermal growth factorreceptor antibody such as Cetuximab, an anti-Her2 antibody, an anti-CD20antibody such as Rituximab, an anti-CD22 antibody such as Inotuzumab,G544 or BU59, an anti-CD70 antibody, an anti-CD33 antibody such ashp67.6 or Gemtuzumab, an anti-MUC1 antibody such as GP1.4 and SM3, ananti-CD40 antibody, an anti-CD74 antibody, an anti-P-cadherin antibody,an anti-EpCAM antibody, an anti-CD138 antibody, an anti-E-cadherinantibody, an (anti-CEA antibody, an anti-FGFR3 antibody, and an antiα4-integrin antibody such as natalizumab.

Table 2A provides nonlimiting examples of cancer types, possibletargeting moieties, and proteases that are expressed by those cancertypes. In order to prepare a two-component system, the cancer may beidentified from column 1, one or two targets chosen for the targetingmoiety (as desired), and one or two proteases chosen for the cancertype, as well (as desired). Other sections of this application discusswhen to use one versus two targeting moieties and one versus twoprotease cleavage sites.

TABLE 2A Coordination of Cancer Type, Targets for Targeting Moiety, andProteases that Can Cleave Cleavage Sites Proteases that can CleaveCancer Targets for Targeting Moiety Cleavage Site Prostate ADAM17, CD59,EpCAM, HER2, KLK3 (PSA), Cancer Integrin αV, Integrin αVβ3, MCP-1, PCLA,KLK4, ADAM17, PSCA, PSMA, RANKL, RG1, SLC44A4 Cathepsin B, uPA, STEAP-1,VEGF-C uPAR, HPN, ST14, TMPRSS2 Breast Cancer CA125, CCN1, CD44, CD98,c-RET, DLL4, MMP2, MMP9, EpCAM, Episialin, GPNMB, HER2/neu, Cathepsin L,HER3, IGF-1R, Integrin α6β4, LFL2, LIV- Cathepsin K, 1, Ly6E, MUC1,MUC18, NRP1, Cathepsin B, Phosphatidylserine, PRLR, TACSTD-2, MMP11,HPN, Tenascin C, TWEAKR, VANGL2, PD-L1, ST14, ADAM28 PD-L2 Myeloma BCMA,IGF-1R, DKK-1, ICAM-1, MMP2, MMP9, CD138/Syndecan1, CD38, GRP78, FGFR3,MMP1, MMP7, SLAMF6, CD48, TfR(CD71) APRIL, CD40, TMPRSS2, CD19, DR5,CXCR4 PRSS22, KLK11 B-cell CD20, CD22, CD19, CD37, CD70, HLA- ADAM28,Lymphoma DR, CD70b Cathepsin B, MMP9 Renal Cell PD-L1, PD-L2, CAIX,TPBG, CD70, ST14, MMP9 carcinoma ENPP3, FGFR1 Gastric VEGFR-2, CLDN18,GCC, C242, MMP2, MMP9, Carcinoma HER2/neu, FGFR2, EpCAM, GPR49,Cathepsin B, uPA, HER3, IGFR uPAR Glioblastoma HER2/neu, EGFR, ALK,EphA2, GD2, MMP2, MMP9, EGFRvIII, ALK T-cell CD2, CD4, CD5, CD71, CD30Cathepsin B, lymphoma Cathepsin D, MMP9 Hodgkin CD30, CD40, IL-3Ra, CD30Cathepsin B Lymphoma Lung Cancer EGFR, IGF-1R, HER3, Integrin α5β1,Cathepsin B, Lewis y/b antigen, EGFL7, TPBG, DKK-1, MMP2, MMP9, NaPi2b,flt4, cMet, CD71 ST14, ADAM17 Pancreatic SLC44A4, uPAR, MUC1, MUCH16,Cathepsin B, ST14, Carcinoma TACSTD-2, CEA, EphhA4, mesothelin, ADAM28EGFR, MUC13, MU5AC, AGF-1R, HER3, CD71 Head and EGFR, EpCAM, HER2Cathepsin B, ST14, Neck cancer ADAM17 Acute myeloid CD33, CD133, CD123,CD45, CD98, c-Kit, ADAM17, leukemia Lewis Y, Siglec-15, FLT-3 CathepsinB, uPA, uPAR Melanoma MUC18, CD40, GD2, CEACAM1, Cathepsin B,Cadherin-19, GM3, Integrin α5β1, TYRP1, MMP9 GD3, Integrin αV OvarianHER2/neu, EpCAM, CA125, DLL4, Cathepsin B, Cancer Integrin αVβ3, MUC5A,NaPi2B, MMP2, MMP9 Mesothelin, CLDN6 Liver Cancer Glypican-3, FGFR4,ENPP3, PIVKA-II, Cathepsin B, PLVAP, cMet, EpCAM MMP9 Colorectal EGFR,Lewis y/b, Progastrin, GPR49, CEA, Cathepsin S, Carcinoma CLDN1, A33,CK8, Integrin αV, EpCAM, Cathepsin L, DLL4, EGFL7, FAP, Cathepsin B,uPA, uPAR, MMP2, MMP9, ST14

For example, when targeting moieties in the first and second componentsare different, Table 2B provides a nonlimiting list of potentialtargeting moieties to use in combination with particular cancer types.In a two-component system, a targeting moiety for the first componentwould be present and a second targeting moiety for the second componentmay optionally be present. If only the first component has a targetingmoiety or if the first and second components have the same targetingmoiety, either the targeting moiety listed in column 1 or column 2 ofthe table may be used when the cancer type is listed in column 3.

TABLE 2B Targeting Moieties for Use in Two-Component System OptionalTargeting Targeting Moiety for Moiety for Second First ComponentComponent Cancer Type Antibody against CD20 Antibody against CD80Lymphoma (such as Rituximab) Antibody against CD20 Antibody against CD22Lymphoma (such as Rituximab) (such as Inotuzumab) Antibody against CD20Antibody against CD70 Lymphoma (such as Rituximab) Antibody against HER2Antibody against EpCAM Epithelial malignancies Antibody against EGFRAntibody against mucin Breast cancer (such as Cetuximab) protein coreAntibody against EGFR Antibody against HER2 Epithelial malignancies(such as Cetuximab) Antibody against EGFR Antibody against Gliomas (suchas Cetuximab) transferrin receptor Antibody against Antibody against p-Drug-resistant melanomas gp95/gp97 glycoprotein Antibody against TRAIL-Antibody against DR5 Multiple malignancies, R1 including ovarian andcolorectal carcinoma Antibody against IL-4 Antibody against IL-6Lymphomas and leukemias Antibody against CD19 Antibody against CD22Lymphoma Antibody against PSMA Antibody against PSCA Prostate carcinomaAntibody against P- Antibody against Cripto Epithelial malignanciescadherin (TDGF1) Antibody against CD74 Antibody against CD40 LymphomasAntibody against PD-L1 Antibody against IGF-1R Epithelial adenocarcinomaAntibody against CD38 Antibody against CD138 Myeloma Antibody againstBCMA Antibody against CD138 Myeloma or CD38 Antibody against CD33Antibody against CD133 Myeloid Malignancies, e.g. AML Antibody againstCD33 Antibody against CD123 Myeloid Malignancies such as AML Antibodyagainst CD49d Antibody against CD33 Myeloid Malignancies Antibodyagainst PSMA Antibody against PSCA Prostate Cancer Antibody againstAntibody against cMet or Hepatocellular carcinoma Glypican 3 EpCAMAntibody against EpCAM Antibody against EGFR Lung Cancer Antibodyagainst EpCAM Antibody against MUC1 Pancreatic Cancer Antibody againstEpCAM Antibody against EGFR Colorectal Carcinoma Antibody against MUC1Antibody against EGFR Ovarian Carcinoma Antibody against GD2 Antibodyagainst HER2 Sarcoma Antibody against HER2 Antibody against HER3 BreastCancer Antibody against IL-13R Antibody against EGFR Brain Cancer

In some embodiments, the targeting moiety is not an antibody, but isanother type of targeting moiety. For example, a targeting moiety may bea binding partner for a protein known to be expressed on the unwantedcell. Such expression levels may include overexpression. For example,the following binding partners may bind to the following targets on anunwanted cell:

TABLE 3 Non-Antibody Binding Partners and Corresponding Targets BindingPartner Target on Unwanted Cell IL-2 IL-2 receptor IL-4 IL-4 receptorIL-6 IL-6 receptor α-MSH MSH receptor (melanocyte stimulating hormonereceptor) Transferrin TR (transferrin receptor) Folic acid FOLR (folatereceptor 1) and/or FOLH1 (folate hydroxylase) EGF and/or TGFα EGFR (EGFreceptor) PD1 PD-L1 and/or PD-L2 IL13 IL-13R (Glioblastoma) Stem cellfactor CXCR4 Insulin-like growth factor (IGF) IGFR CD40 CD40L

The binding partner need not comprise the full length or wildtypesequence for the binding partners listed in Table 3. All that isrequired is that the binding partner bind to the target on the unwantedcell and can thus include truncated forms, analogs, variants, andderivatives that are well known in the art.

Additionally, in some embodiments, the binding partner may be an aptamerthat is capable of binding to a protein known to be expressed on theunwanted cell. Aptamers that bind unwanted cells, such as cancer cells,are well known and methods for designing them are known.

Cell-based SELEX systems may be used to select a panel of targetcell-specific aptamers from a random candidate library. A ssDNA pool maybe dissolved in binding buffer and denatured and then incubated withtarget cells. After washing the bound DNAs may be eluted by heating andthen incubated with negative cells (if desired), centrifuged, and thesupernatant removed. The supernatant may be amplified by PCR with biotinlabeled primers. The selected sense ssDNA may be separated from theantisense biotinylated strand using streptavidin coated beads. Toincrease affinity, washing strength may be increased through increasingwashing time, volume of buffer, and number of washes. After the desiredrounds of selection, the selected ssDNA pool may be PCR amplified andcloned into E. coli and sequenced. See Shangguan et al., Aptamersevolved from live cells as effective molecular probes for cancer study,PNAS 103(32:11838-11843 (2006); Lyu et al, Generating Cell TargetingAptamers for Nano therapeutics Using Cell-SELEX, Theranostics6(9):1440-1452 (2016); see also Li et al., Inhibition of CellProliferation by an Anti-EGFR Aptamer, PLoS One 6(6):e20229 (2011). Thespecific approaches for designing aptamers and specific aptamers bindingto cancer cells in these references are hereby incorporated byreference.

For example, an aptamer may comprise SEQ ID NO: 94 to 164. In someembodiments, an aptamer may comprise SEQ ID NO: 95. These aptamers aredirected to EGFR and are provided only as representative of the aptamersthat can bind to targets presented on unwanted cells. Other aptamersagainst other targets on unwanted cells are equally part of thedescription herein and incorporated by reference as described in Zhu etal., Progress in Aptamer Mediated Drug Delivery Vehicles for CancerTargeting, Theranostics 4(9):931-944 (2014).

In some embodiments, aptamers for use herein bind to the target on theunwanted cell with a K_(d) in the nanomolar to picomolar range (such as1 picomolar to 500 nanomolar or 1 picomolar to 100 nanomolar).

B. T-Cell Engaging Domain

The targeted T-cell engaging agent comprises a first T-cell engagingdomain that is unable of engaging a T-cell alone. Instead, the firstT-cell engaging domain is capable of activity when binding a secondT-cell engaging domain, which is not part of the targeted T-cellengaging agent. Thus, the first and second T-cell engaging domains maybe any two moieties that do not possess T-cell engaging activity alone,but do possess it when paired with each other. In other words, the firstand second T-cell engaging domains are complementary halves of afunctional active protein.

When the two T-cell engaging domains are associated together in thetwo-component system, they may bind to the CD3 antigen and/or T-cellreceptor on the surface of the T-cell as these activate T cells. CD3 ispresent on all T cells and consists of subunits designated γ, δ, ε, ζ,and η. The cytoplasmic tail of CD3 is sufficient to transduce thesignals necessary for T cell activation in the absence of the othercomponents of the TCR receptor complex. Normally, activation of T cellcytotoxicity depends first on binding of the TCR with a majorhistocompatibility complex (MHC) protein, itself bound to a foreignantigen, located on a separate cell. In a normal situation, only whenthis initial TCR-MHC binding has taken place can the CD3 dependentsignally cascade responsible for T cell clonal expansion and,ultimately, T cell cytotoxicity ensue. In some of the presentembodiments, however, when the two-component system binds to CD3 and/orthe TCR, activation of cytotoxic T cells in the absence of independentTCR-MHC can take place by virtue of the crosslinking of the CD3 and/orTCR molecules mimicking an immune synapse formation. This means that Tcells may be cytotoxically activated in a clonally independent fashion,i.e. in a manner that is independent of the specific TCR clone carriedby the T cell. This allows for activation of the entire T cellcompartment rather than only specific T cells of a certain clonalidentity.

In some embodiments, the first T-cell engaging domain is a VH domain andthe second T-cell engaging domain is a VL domain. In other embodiments,the first T-cell engaging domain is a VL domain and the second T-cellengaging domain is a VH domain. In such embodiments, when pairedtogether the first and second T-cell engaging domains may comprise anscFv.

If the first and second T-cell engaging domains are a pair of VH and VLdomains, the VH and VL domains may be specific for an antigen expressedon the surface of a T cell, such as CD3 or TCR. If the antigen is CD3,one potential T-cell engaging domain may be derived from muromonab.

C. Inert Binding Partner

The targeted T-cell engaging agent also comprises at least one inertbinding partner capable of binding the first T-cell engaging domain andpreventing it from binding to a second T-cell engaging domain unlesscertain conditions occur. When the first T-cell engaging domain is boundto the at least one inert binding partner, it does not possess a T-cellengaging activity. In other words, the at least one inert bindingpartner cripples the function of the first T-cell engaging domain byblocking it from binding its complementary pair (the second T-cellengaging domain) and preventing the two domains from joining together tohave a T-cell engaging activity. In other words, the inert bindingpartner binds to the first T-cell engaging domain such that the firstT-cell engaging domain does not bind to the second T-cell engagingdomain unless the inert binding partner is removed. By does not bind,the application does not exclude nonspecific binding or low levels ofbinding (for example, ≤1%, ≤5%, ≤10%).

In some embodiments, the inert binding partner binds specifically to theT-cell engaging domain.

In some embodiments, the at least one inert binding partner is a VH orVL domain. In some embodiments, when the T-cell engaging domain in thetargeted T-cell engaging agent is a VH domain, the inert binding partnermay be a VL domain and when the first T-cell engaging domain is a VLdomain, the inert binding partner may be a VH domain.

If a first component comprises a targeting moiety and a VL T-cellengaging domain and a VH inert binding partner, in some embodiments, theVH inert binding partner has an equilibrium dissociation constant forbinding to the VL T-cell engaging domain, which is greater than theequilibrium dissociation constant of the VL T-cell engaging domain forits partner VH T-cell engaging domain in the second component. In someembodiments, the prior sentence is equally true when VH is switched forVL and vice versa.

Based on empirical evidence in the examples, it is believed that usingthe inert binding partner as a mispairing partner with the T-cellengaging domain in the construct results in constructs that are morestable and easier to manufacture.

D. Cleavage Site

By way of overview, the cleavage site may be (i) cleaved by an enzymeexpressed by the unwanted cells; (ii) cleaved through a pH-sensitivecleavage reaction inside the unwanted cell; (iii) cleaved by acomplement-dependent cleavage reaction; or (iv) cleaved by a proteasethat is colocalized to the unwanted cell by a targeting moiety that isthe same or different from the targeting moiety in the agent. In someembodiments, the cleavage site is a protease cleavage site.

The cleavage sites function to release the inert binding partner fromthe first T-cell engaging domain. The cleavage sites can function indifferent ways to release the inert binding partner from the firstT-cell engaging domain T-cell epitopes in the microenvironment of theunwanted cells. The cleavage may occur inside the unwanted cell oroutside the unwanted cell, depending on the strategy employed. Ifcleavage occurs outside the unwanted cell, the T-cell engaging domaincan be presented without first being internalized into a cell and beingengaged in the classical antigen-processing pathways.

In certain embodiments, at least one cleavage site may be cleaved by anenzyme expressed by the unwanted cells. Cancer cells, for instance, areknown to express certain enzymes, such as proteases, and these may beemployed in this strategy to cleave the targeted T-cell engaging agent'scleavage site. By way of nonlimiting example, cathepsin B cleaves FR,FK, VA and VR amongst others; cathepsin D cleaves PRSFFRLGK (SEQ ID NO:[[45]]42), ADAM28 cleaves KPAKFFRL (SEQ ID NO: 1), DPAKFFRL (SEQ ID NO:2), KPMKFFRL (SEQ ID NO: 3) and LPAKFFRL (SEQ ID NO: 4); and MMP2cleaves AIPVSLR (SEQ ID NO: 46), SLPLGLWAPNFN (SEQ ID NO: 47), HPVGLLAR(SEQ ID NO: 48), GPLGVRGK (SEQ ID NO: 49), and GPLGLWAQ (SEQ ID NO: 50),for example. Other cleavage sites listed in Table 1A or 2A may also beemployed. Protease cleavage sites and proteases associated with cancerare well known in the art. Oncomine (www.oncomine org) is an onlinecancer gene expression database, so when the agent of the invention isfor treating cancer, the skilled person may search the Oncomine databaseto identify a particular protease cleavage site (or two proteasecleavage sites) that will be appropriate for treating a given cancertype. Alternative databases include the European Bioinformatic Institute(www.ebi.ac.uk), in particular (www.ebi.ac.uk/gxa). Protease databasesinclude PMAP (www.proteolysis.org), ExPASy Peptide Cutter(ca.expasy.org/tools/peptidecutter) and PMAP.Cut DB (cutdb.burnham.org).

In some embodiments, at least one cleavage site may be cleaved through apH-sensitive cleavage reaction inside the unwanted cell. If the targetedT-cell engaging agent is internalized into the cell, the cleavagereaction may occur inside the cell and may be triggered by a change inpH between the microenvironment outside the unwanted cell and theinterior of the cell. Specifically, some cancer types are known to haveacidic environments in the interior of the cancer cells. Such anapproach may be employed when the interior unwanted cell type has acharacteristically different pH from the extracellular microenvironment,such as particularly the glycocalyx. Because pH cleavage can occur inall cells in the lysozymes, selection of a targeting agent when using apH-sensitive cleavage site may require, when desired, more specificity.For example, when a pH-sensitive cleavage site is used, a targetingagent that binds only or highly preferably to cancer cells may bedesired (such as, for example, an antibody binding to mesothelin fortreatment of lung cancer).

In certain embodiments, at least one cleavage site may be cleaved by acomplement-dependent cleavage reaction. Once targeted T-cell engagingagents bind to the unwanted cell, the patient's complement cascade maybe triggered. In such a case, the complement cascade may also be used tocleave the inert binding partner from the first T-cell engaging domainby using a cleavage site sensitive to a complement protease. Forexample, C1r and C1s and the C3 convertases (C4B,2a and C3b,Bb) areserine proteases. C3/C5 and C5 are also complement proteases.Mannose-associated binding proteins (RASP), serine proteases alsoinvolved in the complement cascade and responsible for cleaving C4 andC2 into C4b2b (a C3 convertase) may also be used. For example, andwithout limitation, C1s cleaves YLGRSYKV (SEQ ID NO: 73) and MQLGRX (SEQID NO: 74). MASP2 is believed to cleave SLGRKIQI (SEQ ID NO: 75).Complement component C2a and complement factor Bb are believed to cleaveGLARSNLDE (SEQ ID NO: 76).

In some embodiments, at least one cleavage site may be cleaved by aprotease that is colocalized to the unwanted cell by a targeting moietythat is the same or different from the targeting moiety in the targetedT-cell engaging agent. For example, any protease may be simultaneouslydirected to the microenvironment of the unwanted cells by conjugatingthe protease to a targeting agent that delivers the protease to thatlocation. The targeting agent may be any targeting agent describedherein. The protease may be affixed to the targeting agent through apeptide or chemical linker and may maintain sufficient enzymaticactivity when bound to the targeting agent.

In some embodiments, both the first component and second component aremispaired with an inert binding partner. In some embodiments, theprotease cleavage site in the first component and the second componentare the same. In other embodiments, the protease cleavage sites in thefirst component and the second component are different cleavage sitesfor the same protease. In other embodiments, the protease cleavage sitesin the first component and the second component are cleavage sites fordifferent proteases. In some embodiments employing two differentproteases, the unwanted cell expresses both proteases.

In some embodiments, in a first component, the inert binding partner inan uncleaved state interferes with the specific binding of a VL or VHT-cell engaging domain to its partner VH or VL, respectively, T-cellengaging domain in a second component. In some embodiments, the inertbinding partner in an uncleaved state inhibits the binding of the VL orVH T-cell engaging domain to its partner VH or VL, respectively, T-cellengaging domain in a second component such that the dissociationconstant (Kd) of the VL or VH T-cell engaging domain to its partner VHor VL, respectively, T-cell engaging domain in a second component in anuncleaved state is at least 100 times greater than the Kd of the VL orVH T-cell engaging domain to its partner VH or VL, respectively, T-cellengaging domain in a second component in a cleaved state.

E. Linkers

In addition to the cleavage site, linkers may optionally be used toattach the separate parts of the targeted T-cell engaging agentstogether. By linker, we include any chemical moiety that attaches theseparts together. In some embodiments, the linkers may be flexiblelinkers. Linkers include peptides, polymers, nucleotides, nucleic acids,polysaccharides, and lipid organic species (such as polyethyleneglycol). In some embodiments, the linker is a peptide linker Peptidelinkers may be from about 2-100, 10-50, or 15-30 amino acids long. Insome embodiments, peptide linkers may be at least 10, at least 15, or atleast 20 amino acids long and no more than 80, no more than 90, or nomore than 100 amino acids long. In some embodiments, the linker is apeptide linker that has a single or repeating GGGGS (SEQ ID NO: 85),GGGS (SEQ ID NO: 86), GS (SEQ ID NO: 87), GSGGS (SEQ ID NO: 88), GGSG(SEQ ID NO: 89), GGSGG (SEQ ID NO: 90), GSGSG (SEQ ID NO: 91), GSGGG(SEQ ID NO: 92), GGGSG (SEQ ID NO: 93), and/or GSSSG (SEQ ID NO: 94)sequence(s).

In some embodiments, the linker is a maleimide (MPA) or SMCC linker.

F. Methods of Making

The targeted T-cell engaging agents as described herein can be madeusing genetic engineering techniques. Specifically, a nucleic acid maybe expressed in a suitable host to produce a targeted T-cell engagingagent. For example, a vector may be prepared comprising a nucleic acidsequence that encodes the targeted T-cell engaging agent including allof its component parts and linkers and that vector may be used totransform an appropriate host cell.

Various regulatory elements may be used in the vector as well, dependingon the nature of the host and the manner of introduction of the nucleicacid into the host, and whether episomal maintenance or integration isdesired.

Chemical linkage techniques, such as using maleimide or SMCC linkers,may also be employed.

In instances where the binding partner is an aptamer, a person ofordinary skill in the art would appreciate how to conjugate an aptamerto a protein, namely the T-cell engaging domain. Aptamers may beconjugated using a thiol linkage or other standard conjugationchemistries. A maleimide, succinimide, or SH group may be affixed to theaptamer to attach it to the T-cell engaging domain.

II. Pharmaceutical Compositions

The targeted T-cell engaging agents may be employed as pharmaceuticalcompositions. As such, they may be prepared along with apharmaceutically acceptable carrier. If parenteral administration isdesired, for instance, the targeted T-cell engaging agents may beprovided in sterile, pyrogen-free water for injection or sterile,pyrogen-free saline. Alternatively, the targeted T-cell engaging agentsmay be provided in lyophilized form for resuspension with the additionof a sterile liquid carrier.

III. Methods of Treatment

A. Reduction of Unwanted Cells, Targeting of Immune Response, andTreatment of Cancer

The targeted T-cell engaging agents described herein may be used in amethod of treating a disease in a patient characterized by the presenceof unwanted cells comprising administering a two-component systemcomprising at least one targeted T-cell engaging agent and a secondcomponent to the patient, as each of the components have been describedin detail in various embodiments above. Additionally, the agentsdescribed herein may also be used in a method of targeting a patient'sown immune response to unwanted cells comprising administering atwo-component system to the patient.

The amount of the agent administered to the patient may be chosen by thepatient's physician so as to provide an effective amount to treat thecondition in question. The first component and the second component ofthe two-component system may be administered in the same formulation ortwo different formulations within a sufficiently close period of time tobe active in the patient.

The patient receiving treatment may be a human. The patient may be aprimate or any mammal. Alternatively, the patient may be an animal, suchas a domesticated animal (for example, a dog or cat), a laboratoryanimal (for example, a laboratory rodent, such as a mouse, rat, orrabbit), or an animal important in agriculture (such as horses, cattle,sheep, or goats).

The condition characterized by unwanted cells may include cancer. Thecancer may be a solid or non-solid malignancy. The cancer may be a solidtumor wherein the solid tumor is not a lymphoma. The cancer may be anycancer such as breast cancer, ovarian cancer, endometrial cancer,cervical cancer, bladder cancer, renal cancer, melanoma, lung cancer,prostate cancer, testicular cancer, thyroid cancer, brain cancer,esophageal cancer, gastric cancer, pancreatic cancer, colorectal cancer,liver cancer, leukemia, myeloma, nonHodgkin lymphoma, Hodgkin lymphoma,acute myeloid leukemia, acute lymphoblastic leukemia, chroniclymphoblastic leukemia, lymphoproliferative disorder, myelodysplasticdisorder, myeloproliferative disease and premalignant disease.

The two-component system may be administered alone or in conjunctionwith other forms of therapy, including surgery, radiation, ortraditional chemotherapy.

EXAMPLES Example 1. Preparation of Constructs

Various constructs, both control and experimental, were prepared andused in the examples.

A. Single Chain scFv Bispecific Constructs

A single chain scFv construct was used in this application in order toserve as a positive control. Construct 6245 (SEQ ID NO: 165) wasprepared as a bispecific antibody comprising an anti-EPCAM scFv andanti-CD3E scFv. This construct does not comprise any mispairing with aninert binding partner and has both active targeting and T-cell engagingmoieties.

B. Precleaved Two-Component System Constructs Using a Targeting scFv

Construct 6246 (SEQ ID NO: 166) and 6247 (SEQ ID NO: 167) arecomplementary precleaved constructs in a two-component system. Byprecleaved, the description refers to a construct with a functionaltargeting moiety and an unpaired T-cell engaging moiety (i.e., one thatis not mispaired to an inert binding partner and one that is also notyet paired with its correct partner to form a functional T-cell engagingcomplex). Both constructs comprise an anti-EPCAM scFv. Construct 6246comprises an anti-CD3E VH domain, whereas construct 6247 comprises ananti-CD3E VL domain. Neither construct contains an inert binding partneras a mispairing partner.

C. Two-Component System Constructs Using a Targeting scFv and a T-CellEngaging Domain Mispaired to an Inert Binding Partner, as Well as aProtease Cleavage Site for Releasing the Inert Binding Partner

Construct 6248 (SEQ ID NO: 168) and 6249 (SEQ ID NO: 169) arecomplementary constructs in a two-component system. Both constructscomprise an anti-EPCAM scFv. Construct 6248 comprises an anti-CD3E VHdomain linked through a 25-mer linker having an MMP2 cleavage site(AIPVSLR (SEQ ID NO: 46)) to an inert binding partner VL domain fromgantenerumab. Construct 6249 comprises an anti-CD3E VL domain linkedthrough a 25-mer linker having an MMP2 cleavage site (AIPVSLR (SEQ IDNO: 46)) to an inert binding partner VH domain from clone alpha-MUC1-1antibody.

D. Two-Component System Constructs with a Targeting Moiety, and a T-CellEngaging Domain Mispaired with an Inert Binding Partner without aProtease Cleavage Site for Releasing the Inert Binding Partner

Constructs 9327 (SEQ ID NO: 170) and 9328 (SEQ ID NO: 171) aretwo-component system constructs using an scFv targeting domain; however,they do not have a protease cleavage site for releasing the inertbinding partner that serves as a mispairing moiety. Both constructscomprise an anti-EpCAM scFv for targeting the constructs to the unwantedcells expressing EpCAM. Construct 9327 comprises an anti-CD3E VH domainlinked by a 25-mer linker that does not have a protease cleavage sitecorresponding to a protease used in the examples to an inert bindingpartner VL domain from gantenerumab. Construct 9328 comprises ananti-CD3E VL domain linked by a 25-mer linker that does not have aprotease cleavage site corresponding to a protease used in the examplesto an inert binding partner VH domain from clone alpha-MUC1-1 antibody.

Because these constructs do not have a protease cleavage sitecorresponding to a protease used in the examples, the inert bindingpartner will remain attached to the construct, preventing the twowould-be complementary components of the two-component system fromcoming together to create an active anti-CD3E scFv.

E. Constructs Providing Different Targeting Moieties

Constructs 9329 (SEQ ID NO: 172) and 9330 (SEQ ID NO: 173) providedifferent targeting moieties. These constructs were intended to be usedin two-component systems where one construct targets a first antigen ona cancer cell and the second construct targets a second antigen on thesame cancer cell. Because the relative size of scFv and VHH targetingmoieties are similar, these constructs were intended to “mix-and-match”with the pairable constructs having an anti-CD3E VL domain.

Construct 9329 comprises an anti-glypican-3 VHH sequence. It alsocomprises an anti-CD3E VH domain attached by a 25-mer linker comprisingan MMP2 cleavage site (AIPVSLR (SEQ ID NO: 46)) to an inert bindingpartner VL domain from gantenerumab.

Construct 9330 comprises an anti-SDC1 scFv from indatuximab as thetargeting moiety. It also comprises an anti-CD3E VH domain attached by a25-mer linker comprising an MMP2 cleavage site (AIPVSLR (SEQ ID NO: 46))to an inert binding partner VL domain from gantenerumab.

F. VHH/scFv Bispecific Constructs

Construct 9332 (SEQ ID NO: 174) and 9333 (SEQ ID NO: 175) are bothVHH/scFv bispecific constructs comprising an anti-EGFR VHH portion andan anti-CD3E scFv portion. These two constructs do not comprise anyinsert binding domain.

G. Two-Component System Constructs Using a Targeting VHH Domain, aT-Cell Engaging Domain Mispaired to an Inert Binding Partner andComprising a Protease Cleavage Site for Releasing the Inert BindingPartner

Constructs 9334 (SEQ ID NO: 176) and 9335 (SEQ ID NO: 177) arecomplementary two-component system constructs using a targeting VHHdomain. Both constructs comprise an anti-EGFR VHH domain for targetingto the unwanted cells expressing EGFR. Construct 9334 comprises ananti-CD3E VH domain linked by a 25-mer linker having an MMP2 cleavagesite (AIPVSLR (SEQ ID NO: 46)) to an inert binding partner VL domainfrom gantenerumab. Construct 9335 was prepared comprising an anti-CD3EVH domain linked by a 25-mer linker having an MMP2 cleavage site(AIPVSLR (SEQ ID NO: 46)) to an inert binding partner VH domain fromclone alpha-MUC1-1 antibody.

Thus, as a summary, the constructs are as provided in Table 4, with moredetail and sequences provided above in Table 1B, with IBD standing forInert binding partner.

TABLE 4 Construct Summary T-Cell Targeting Engaging IBD? No. MoietyMoiety? Cleavage? Pair with? 6245 anti-EpCAM anti-CD3E no IBD, no nopairing necessary scFv scFv cleavage for TCE activity (positive control)6246 anti-EPCAM anti-CD3E no IBD, no pairs with at least 6247 scFv VHcleavage 6247 anti-EPCAM anti-CD3E no IBD, no pairs with at least 6246scFv VL cleavage 6248 anti-EPCAM anti-CD3E MMP2 pairs with at least 6249scFv VH cleavage site and inert VL 6249 anti-EPCAM anti-CD3E MMP2 pairswith at least 6248 scFv VL cleavage site and inert VH 9327 anti-EpCAManti-CD3E no cleavage cannot easily pair with scFv VH site and inert9328 because no VL cleavage site (negative control) 9328 anti-EpCAManti-CD3E no cleavage cannot easily pair with scFv VL site and inert9327 because no VH cleavage site (negative control) 9329 anti-Glypican-3anti-CD3E MMP2 “mix-and-match” with VHH VH cleavage site pairableconstructs and inert VL having an anti-CD3E VL domain 9330 anti-SDC1scFv anti-CD3E MMP2 “mix-and-match” with from VH cleavage site pairableconstructs indatuximab and inert VL having an anti-CD3E VL domain 9332anti-EGFR anti-CD3E no IBD, no no pairing necessary VHH (7D12) scFvcleavage for TCE activity (positive control) 9333 anti-EGFR anti-CD3E noIBD, no no pairing necessary VHH (9D8) scFv cleavage for TCE activity(positive control) 9334 anti-EGFR anti-CD3E MMP2 pairs with at least9335 VHH VH cleavage site and inert VL 9335 anti-EGFR anti-CD3E MMP2pairs with at least 9334 VHH VL cleavage site and inert VH

H. Preparation and Storage of All Constructs

Constructs were generated by DNA2.0 (Newark, Calif.) and expressed inHEK293T cells. Single-stranded oligonucleotides were designed to cover aspecified sequence with a C-terminal hexahistidine tag to aid withdown-stream purification. The oligonucleotides were chemicallysynthesized, then assembled using a variety of proprietary protocolsdepending on the sequence characteristics. In some instances, templateindependent PCR was used. In some instances, smaller sequences wereassembled to create larger sequences by use of standard restrictionenzyme digestion and ligase-mediated assembly. The assembledoligonucleotides were then cloned into standard E. coli plasmids and thecomplete double strand sequence verified by automated Sanger sequencingon ABI hardware. Constructs were expressed by transient transfection inHEK293T cells at the 150 ml scale and antibody fragments purified usingaffinity chromatography.

Before experiments began, constructs were thawed on ice and aliquotedunder sterile conditions into low protein-binding tubes. Aliquots werestored at −80° C. until required. Aliquots were thawed on iceimmediately prior to use. Aliquots were used for a maximum of fivefreeze-thaw cycles.

Example 2. Evaluation Construct Manufacturing

A. FIG. 5A: Evaluation of Constructs by SDS PAGE and Coomassie BlueStaining

Aliquots of antibody were thawed on ice, and diluted in 25 mM Tris pH7.4to a final concentration of 2.0 mg/ml. If the constructs were alreadymore dilute than this, the dilution step was omitted. An appropriatevolume of 6× gel sample buffer (0.5 M Tris pH 6.8, 12% (w/v) SDS, 25%(v/v) glycerol, 5 mM EDTA, 200 mM N-ethylmaleimide) was added to eachsample, which was then heated to 90° C. for 10 minutes.

10 μg of each construct was run on a 4-20% pre-cast gradient gel. Oncerun, gels were fixed for 30 minutes in stain buffer (10% (v/v) aceticacid, 50% (v/v) methanol and 40% (v/v) dH₂O) and then stained for 2hours in Coomassie blue R-250 (0.25% in stain buffer), followed byde-staining for 2 to 3 hours in stain buffer with several changes ofbuffer as required. Gels were stored in 7% (v/v) acetic acid beforedocumentation.

Results are shown in FIG. 5A. This shows that the proteins have beenmade and have very high purity, along with the correct molecular masspredicted by their sequence.

B. FIG. 5B

Additional constructs were evaluated in FIG. 5B. The method used forFIG. 5A was used for 5B.

Constructs 6245 (the bispecific construct not requiring pairing), 6248and 6248 (pairable constructs with an inert binding partner and an MMP2cleavage site) were produced adequately. Constructs 6246 and 6247 (notcontaining an inert binding partner) were produced at low yields and arebelieved to be unstable. It is likely that the VH/VL pairing isimportant for fragment stability.

Thus, we believe that the constructs mispaired with an inert bindingpartner are more stable and easier to manufacture.

C. Yield

The yield of the constructs assessed in FIG. 5B was as follows:

TABLE 5 Yields Construct Yield (mg) 6245 13.29 6246 0.57 6247 3.24 624817.54 6249 43.52

Example 3. Evaluation of IFNγ Expression in T-Cells Cells Mixed withTumor Cell Lines and Treated with Various Constructs

Preparations of single constructs and mixed constructs were tested fortheir IFNγ expression in order to test the ability of the complementaryconstructs in a two-component system to elicit a T-cell response.

Background of IFNγ Assays Generally: Expression of cytokine markers invitro, such as IFNγ expression, is known to have a predictive value forT cell responses and, thus, predicts in vivo results. As described inGhanekar et al., Clin Diag Lab Immunol j8(3):628-31 (2001), IFNγexpression in CD8+ T cells measured by cytokine flow cytometry (CFC) isa surrogate marker for the response of cytotoxic T lymphocytes. Ghanekarat 628. Prior work showed that there is a strong correlation between theexpression of IFNγ by CD8+ T cells and the activity of CTL effectorcells. Ghanekar at 630. Prior work shows that the use of data on IFNγexpression allows greater accuracy in assessing CD8+ T-cell responses ina clinical setting. Id. at 631. This demonstrates that the cytokineexpression assays herein were known to have predictive value for in vivoand clinical responses. While the methods herein do not follow the exactmethod steps of Ghanekar because there are multiple ways to assess IFNγexpression, Ghanekar demonstrates that IFNγ expression is a proxy forT-cell activity.

T Cell Line Culture:

Cytotoxic T cells were used in the IFNγ assays and cultured in RPMI-1640medium containing 4.0 mM L-glutamine, 1% penicillin and streptomycin,10% heat-inactivated FBS, 1% heat-inactivated human serum (pooled ABserum, TCS Bioscience) and 1,000 U/ml IL-2. Cells were kept at a densityof 1-2×10⁶ cells/ml, and were fed by replacement of three quarters ofthe medium every 48 hours. They were originally generated by adding 10ug HLA-A*0201-restricted viral peptide NLVPMVATV (SEQ ID NO: 178) to 10million peripheral blood mononuclear cells (PBMCs) from an HLA-A*0201+donor. Cells were cultured in RPMI-1640 medium containing 4.0 mML-glutamine, 1% penicillin and streptomycin, 10% heat-inactivated FBSand 1% heat-inactivated human serum (pooled AB serum, TCS Bioscience)for four days before the media was changed to include 1000 U/ml IL-2.The T cells were predominantly CD8+ T cells with a small amount of CD4+T cells as well.

Tumor Cell Line Culture:

The following cell lines were used: SW620, MCF-7, SNU398, and U266.Cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution except SNU398 and U266 cells which werecultured in RPMI-1640 medium containing 10% heat-inactivated FBS, 2 mMglutamine and 1% penicillin/streptomycin solution. SW620 cells arederived from a human colon cancer metastasis. MCF-7 cells are derivedfrom a human breast cancer metastatic site (pleural effusion). SNU398cells are derived from a human anaplastic hepatocellular carcinomapatient in 1990. U266 cells are derived from a human male multiplemyeloma patient secreting IgE.

Impact of Constructs on IFNγ Production:

Adherent cell lines were plated in a 96 well plate (100,000 cells perwell) for at least 16 hours. Non-adherent cells (100,000 cells per well)were plated on the day of the experiment by centrifuging the culture at400×g for 5 minutes and resuspending the cells in T cell medium. 20,000T cells per well in T cell medium were added. Constructs were made up inT cell medium and added to the cultures. Where mixtures of constructswere used, these were pre-mixed before addition to the cultures. Thefinal volume in the culture was 200 μl per well. Cultures were incubatedfor 24 hours at 37° C., 5% CO₂ and 100% relative humidity. The cultureswere centrifuged at 400×g for 5 minutes and the supernatants aspiratedand placed in a separate plate. Supernatants were stored at −20° C.until analyzed for IFNγ.

IFNγ ELISA:

IFNγ levels in tissue culture supernatants were assayed using either aneBioscience Ready-Set-Go ELISA kit (cat. no. 88-7316-88) or a BioLegendHuman IFNγ ELISA Max kit (cat. no. 430106) as per the manufacturer'sinstructions.

A. FIG. 6

IFNγ was evaluated for various single constructs and mixed constructs.The IFNγ production and ELISA assay protocols provided above were used,except as noted. SW620 cells were cultured in DMEM containing 10% FBS,and 1% penicillin/streptomycin solution. Cells were plated in a 96 wellplate (100,000 cells per well) on the day prior to the experiment. Onthe day of the experiment the medium was aspirated and discarded. 20,000T cells per well in T cell medium were added. Constructs (finalconcentration of 1 μg/ml) were made up in T cell medium and added to theculture. Controls were PHA-M (final concentration 10 μg/ml), SW620 cellsplus T cells with no additions, and SW620 cells without T cells or otheradditions. Each condition was run in triplicate. The final volume in theculture was 200 μl per well. The culture was incubated for 24 hours at37° C., 5% CO2 and 100% relative humidity. The culture was centrifugedat 400×g for 5 minutes and the supernatants aspirated and placed in aseparate plate. Supernatants were stored at −20° C. until analyzed forIFNγ.

IFNγ was evaluated for various single constructs and mixed constructs.Single constructs were assessed, with construct 6425 (a bispecific scFvfor EpCAM and CD3E) was serving as a positive control. Baseline IFNγ wasassessed in T-cells with SW620 cancer cells, SW620 cancer cells alone,and T-cells stimulated nonspecifically with phytohemagglutinin (PHA) toshow the capacity of T-cells for IFNγ expression.

In SW620 tumor cells, constructs were used at a final concentration of 1μg/ml. Cultures were incubated for 4 hours and the supernatants wereassayed for IFNγ. Mean±standard deviation of triplicates are provided.was evaluated for various single constructs and mixed constructs.Cultures were incubated for 4 hours and the supernatants were assayedfor IFNγ. Mean±standard deviation of triplicates are provided.Constructs were used at a final concentration of 1 μg/ml. Cultures wereincubated for 24 hours and the supernatants were assayed for IFNγ.Mean±standard deviation of triplicates are provided.

Construct 6245 serves as a positive control because this construct hasboth a targeting anti-EpCAM scFv and an anti-CD3E scFv; thus, it is abispecific construct not requiring pairing for T-cell engaging (TCE)activity.

Constructs 6248 and 6249 (pairs of a two-component system each having aninert binding partner separated from the anti-CD3E T-cell engaging VL orVH, respectively, by a linker with an MMP2 cleavage site) showed moreIFNγ expression when paired together than when administered alone. Thecombination of 6246 and 6247 (pairs of a two-component system withoutany mispairing to an inert binding partner or protease cleavage siterequired for them to associate) yield a much lower response than thecombination of 6248 and 6249 likely because the 6246 and 6247 are notprotected during manufacturing by the inert binding partner, which isbelieved to stabilize the unpaired anti-CD3E VH and VL domains in eachconstruct, respectively. Thus, we believe that the mispaired constructshaving an inert binding partner are more stable and easier tomanufacture than precleaved constructs having an unpaired anti-CD3E VHor VL domain.

B. FIG. 7

IFNγ was evaluated for various single constructs and mixed constructs.SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentration of1 μg/ml) were made up in T cell medium and added to the culture. Wheremixtures of constructs were used, these were pre-mixed before additionto the cultures (final concentration of constructs was 1 μg/ml perconstruct). Controls were PHA-M (final concentration 10 μg/ml), SW620cells plus T cells with no additions, and SW620 cells without T cells orother additions. Each condition was run in triplicate. The final volumein the culture was 200 μl per well. The culture was incubated for 24hours at 37° C., 5% CO₂ and 100% relative humidity. The culture wascentrifuged at 400×g for 5 minutes and the supernatants aspirated andplaced in a separate plate. Supernatants were stored at −20° C. untilanalyzed for IFNγ. Mean±standard deviation of triplicates are provided.

Construct 6245 serves as a positive control because this construct hasboth a targeting anti-EpCAM scFv and an anti-CD3E scFv; thus, it is abispecific construct not requiring pairing for T-cell engaging (TCE)activity.

Constructs 6248 and 6249 (pairs of a two-component system each having aninert binding partner separated from the anti-CD3E T-cell engaging VL orVH, respectively, by a linker with an MMP2 cleavage site) showed moreIFNγ expression when paired together than when administered alone. Thecombination of 6246 and 6247 (pairs of a two-component system withoutany binding domain or protease cleavage site required for them toassociate) yield a much lower response than the combination of 6248 and6249 likely because the 6246 and 6247 are not protected duringmanufacturing by the inert binding partner, which is believed tostabilize the unpaired anti-CD3E VH and VL domains in each construct,respectively. Thus, we believe that the mispaired constructs having aninert binding partner are more stable and easier to manufacture thanconstructs with an unpaired anti-CD3E VH or VL domain.

C. FIG. 8

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentrationranging from 1 ng/ml to 1 μg/ml) were made up in T cell medium and addedto the culture. Where mixtures of constructs were used, these werepre-mixed before addition to the cultures (final concentration ofconstructs ranged from 1 ng/ml to 1 μg/ml per construct). Controls wereSW620 cells plus T cells with no additions, and SW620 cells without Tcells or other additions. Each condition was run in triplicate. Thefinal volume in the culture was 200 μl per well. The culture wasincubated for 24 hours at 37° C., 5% CO₂ and 100% relative humidity. Theculture was centrifuged at 400×g for 5 minutes and the supernatantsaspirated and placed in a separate plate. Supernatants were stored at−20° C. until analyzed for IFNγ. Mean±standard deviation of triplicateswere shown in FIG. 8.

Construct 6245 served as a positive control and paired constructs 6248and 6249 were assessed. Both the control construct and the pairedtwo-component system showed IFNγ expression. This demonstrates that theinert VL and VH domains are being cleaved from constructs 6248 and 6249,respectively, and that these two constructs are pairing to create acomplete anti-CD3E scFv, which is capable of engaging T cells.

The two-component system (6248 and 6249) has a lower potency than thebispecific 6245 construct, yet is still in an acceptable range and mayactually offer dosing advantages in avoiding side effects.

D. FIGS. 9A-B

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentrationranging from 1 ng/ml to 1 μg/ml) were made up in T cell medium and addedto the culture. Where mixtures of constructs were used, these werepre-mixed before addition to the cultures (final concentration ofconstructs ranged from 10 ng/ml to 10 μg/ml per construct). Controlswere PHA-M (final concentration 10 μg/ml), SW620 cells plus T cells withno additions, and SW620 cells without T cells or other additions. Eachcondition was run in triplicate. The final volume in the culture was 200μl per well. The culture was incubated for 24 hours at 37° C., 5% CO₂and 100% relative humidity. The culture was centrifuged at 400×g for 5minutes and the supernatants aspirated and placed in a separate plate.Supernatants were stored at −200° C. until analyzed for IFNγ.Mean±standard deviation of triplicates were shown in FIGS. 9A-B.

Both the control construct and the paired two-component system showedIFNγ expression. This demonstrates that the inert VL and VH domains arebeing cleaved from constructs 6248 and 6249, respectively, and thatthese two constructs are pairing to create a complete anti-CD3E scFv,which is capable of engaging T cells.

The two-component system (6248 and 6249) has a lower potency than thebispecific 6245 construct, yet is still in an acceptable range and mayactually offer dosing advantages in avoiding side effects.

E. FIG. 10

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentration of1 μg/ml) were made up in T cell medium and added to the culture. Wheremixtures of constructs were used, these were pre-mixed before additionto the cultures (final concentration of constructs was 1 μg/ml perconstruct). Controls were PHA-M (final concentration 10 μg/ml), SW620cells plus T cells with no additions, and SW620 cells without T cells orother additions. Each condition was run in triplicate. The final volumein the culture was 200 μl per well. The culture was incubated for 24hours at 37° C., 5% CO₂ and 100% relative humidity. The culture wascentrifuged at 400×g for 5 minutes and the supernatants aspirated andplaced in a separate plate. Supernatants were stored at −20° C. untilanalyzed for IFNγ. FIG. 10 provides mean±standard deviation oftriplicates.

FIG. 10 shows a very low level of IFNγ expression for constructs withonly a VH or VL for the anti-CD3E scFv; however, positive bispecificconstructs with a full scFv (9332 and 9333) showed higher IFNγexpression levels.

F. Stoichiometric Assessment of Complementary Constructs of aTwo-Component System (FIG. 11)

Complementary constructs of a two-component system (6248 and 6249) wereadded together in varying ratios, as shown in FIG. 11.

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs were pre-mixed in thespecified ratios in T cell medium and added to the culture (finalconcentration of constructs was 1 μg/ml in total). The two components6248 and 6249, one containing the VH domain of the CD3 activating moiety(6249) and the other containing the VL domain of the CD3 activatingmoiety (6248), were pre-mixed at ratios 100:0, 90:10, 75:25, 50:50,25:75, 10:90 and 0:100. The mixtures of the two components were added to100,000 unwanted tumor cells and 20,000 T cells. Controls were PHA-M(final concentration 10 μg/ml), SW620 cells plus T cells with noadditions, and SW620 cells without T cells or other additions. Eachcondition was run in triplicate. The final volume in the culture was 200μl per well. The culture was incubated for 24 hours at 37° C., 5% CO₂and 100% relative humidity. The culture was centrifuged at 400×g for 5minutes and the supernatants aspirated and placed in a separate plate.Supernatants were stored at −20° C. until analyzed for IFNγ.

The results in FIG. 11 demonstrate an increasing activation of T cellsas the ratio of the two components reaches equilibrium. When there is anexcess of either the component containing the VH domain of the CD3activating moiety (6249) or the other component containing the VL domainof the CD3 activating moiety (6248), the activation of T cells isdecreased as the activation is reliant on both the VH and VL of the CD3activating moiety coming together. Therefore, IFNγ expression levelswere much lower when all or nearly all of the constructs provided wereof one type or the other. The highest IFNγ expression level correspondsto the scenario where an equal amount of each of the two complementaryconstructs were provided. This provides further evidence demonstratingthat the IFNγ expression is caused by the two halves of the anti-CD3EscFv coming together from the two constructs in the two-componentsystem.

G. Use of MCF-7 Cells (FIG. 12)

FIG. 12 shows experiments conducted in the MCF-7 tumor cell line. MCF-7cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentration of1 μg/ml) were made up in T cell medium and added to the culture.Controls were PHA-M (final concentration 10 μg/ml), MCF-7 cells plus Tcells with no additions, and MCF-7 cells without T cells or otheradditions. Each condition was run in triplicate. The final volume in theculture was 200 μl per well. The culture was incubated for 24 hours at37° C., 5% CO₂ and 100% relative humidity. The culture was centrifugedat 400×g for 5 minutes and the supernatants aspirated and placed in aseparate plate. Supernatants were stored at −20° C. until analyzed forIFNγ.

Similar results were achieved to the other cell lines used. In FIG. 12,positive control constructs 6245, 9332, and 9333 (each having a fullanti-CD3E scFv) showed much higher IFNγ expression levels than any ofthe single components comprising only a VH or VL domain from theanti-CD3E antibody. FIG. 12 also provides baseline IFNγ expressionlevels for MCF-7 cells alone or T-cells stimulated nonspecifically withPHA.

H. FIGS. 13-14

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentration of1 μg/ml) were made up in T cell medium and added to the culture. Wheremixtures of constructs were used, these were pre-mixed before additionto the cultures (final concentration of constructs was 1 μg/ml perconstruct). Controls were PHA-M (final concentration 10 μg/ml), SW620cells plus T cells with no additions, and SW620 cells without T cells orother additions. Each condition was run in triplicate. The final volumein the culture was 200 μl per well. The culture was incubated for 24hours at 37° C., 5% CO₂ and 100% relative humidity. The culture wascentrifuged at 400×g for 5 minutes and the supernatants aspirated andplaced in a separate plate. Supernatants were stored at −20° C. untilanalyzed for IFNγ.

In FIG. 13, the data show that the two-component system of 6248 and 6249functions as expected because these constructs have an inert bindingpartner that can be cleaved by an MMP2 cleavage site and pairableanti-CD3E variable domains (one VH in 6248 and one VL in 6249).Constructs 9327 and 9328 do not generate a strong IFNγ signal becauseneither of these constructs has a cleavage site between the inertbinding partner and the anti-CD3E variable domain.

Constructs 9327 and 6248 do not show any activity because they both haveVH domains for the anti-CD3E antibody and cannot make a functionalanti-CD3E scFv; additionally, 9327 does not have a cleavage site. 9327and 6249 show a very low level of activity because 9327 has no cleavagesite and 6249 has a cleavage site, but the two together can make ananti-CD3E scFv if some low level of spontaneous cleavage occurs.

In FIG. 14, the pairing of constructs 9334 and 9335 (providingbiparatopic approach to targeting EFGR, with targeting antibody scFvs todifferent epitopes on EGFR) did not create an IFNγ signal. It isbelieved that either the epitopes on EGFR were too far apart for the twoanti-CD3E variable domains to reach each other or the epitopes were tooclose and creating steric hindrance for binding on the antibody side. Itis, however, very reasonable to test biparatopic combinations. Anotherantibody for EGFR can be identified and tested for combinations in thisapproach.

FIG. 14 also shows targeting two different proteins expressed on thesame cancer cell. Construct 6248 binds EpCAM and is successfully pairedwith 9335, which binds EGFR. Construct 6249 also binds EpCAM and issuccessfully paired with 9334. This establishes that different moleculeson a cancer cell may be targeted, providing yet a further layer ofspecificity for some embodiments of the two-component system describedherein. This also provides further evidence that components 9335 and9334 work in other contexts and further suggests these components wereeither too close or too far from each other in their combination witheach other described above.

The combination of 9334 and 6249 provides useful information in thisfigure, demonstrating that dual targeting can be achieved becauseconstruct 9334 targets EGFR and 9249 targets EpCAM.

The combination of 9334 and 6248 was not expected to have activitybecause both constructs comprise a VH from the anti-CD3E antibody andneither construct comprises a VL from that antibody.

I. FIG. 15

SNU398 cells were cultured in RPMI1640 containing 10% FBS, 2 mMglutamine and 1% penicillin/streptomycin solution. Cells were plated ina 96 well plate (100,000 cells per well) on the day prior to theexperiment. On the day of the experiment the medium was aspirated anddiscarded. 20,000 T cells per well in T cell medium were added.Constructs (final concentration of 1 μg/ml) were made up in T cellmedium and added to the culture. Where mixtures of constructs were used,these were pre-mixed before addition to the cultures (finalconcentration of constructs was 1 μg/ml per construct). Controls werePHA-M (final concentration 10 μg/ml), SNU398 cells plus T cells with noadditions, and SNU398 cells without T cells or other additions. Eachcondition was run in triplicate. The final volume in the culture was 200μl per well. The culture was incubated for 24 hours at 37° C., 5% CO₂and 100% relative humidity. The culture was centrifuged at 400×g for 5minutes and the supernatants aspirated and placed in a separate plate.Supernatants were stored at −20° C. until analyzed for IFNγ.

FIG. 15 shows that adding a protease inhibitor reduces the IFNγexpression of the two-component system having a protease cleavage site(constructs 6248 and 6249). The protease inhibitor does not impact the6245 bispecific construct as cleavage and pairing are not required foractivity.

J. FIG. 16

SW620 cells were cultured in DMEM containing 10% FBS, and 1%penicillin/streptomycin solution. Cells were plated in a 96 well plate(100,000 cells per well) on the day prior to the experiment. On the dayof the experiment the medium was aspirated and discarded. 20,000 T cellsper well in T cell medium were added. Constructs (final concentration of1 μg/ml) were made up in T cell medium and added to the culture. Wheremixtures of constructs were used, these were pre-mixed before additionto the cultures (final concentration of constructs was 1 μg/ml perconstruct). Controls were PHA-M (final concentration 10 μg/ml), SW620cells plus T cells with no additions, and SW620 cells without T cells orother additions. Each condition was run in triplicate. The final volumein the culture was 200 μl per well. The culture was incubated for 24hours at 37° C., 5% CO₂ and 100% relative humidity. The culture wascentrifuged at 400×g for 5 minutes and the supernatants aspirated andplaced in a separate plate. Supernatants were stored at −20° C. untilanalyzed for IFNγ.

The functional combination of 9335 and 6248 shows that different kindsof antibody fragments may be combined in a first component and secondcomponent, respectively. 9335 employs an anti-EGFR VHH as the targetingmoiety and 6248 employs an anti-EPCAM scFv as the targeting moiety.

Example 4. In Vivo Targeting of B Cell Lymphoma Using a Two-ComponentSystem

A two-component system comprising a first component and a secondcomponent are administered to a patient having lymphoma. The firstcomponent comprises Rituximab or an anti-CD22 antibody as a targetingmoiety, a VH domain from an antibody binding CD3 as a T-cell engagingdomain, a VL domain as an inert binding partner, and the ADAM28 cleavagesite KPAKFFRL (SEQ ID NO: 1). The second component also comprisesRituximab or an anti-CD22 antibody as a targeting moiety, thecomplementary VL domain from an antibody binding CD3 as a T-cellengaging domain, VH as an inert binding partner, and the ADAM28 cleavagesite KPAKFFRL (SEQ ID NO: 1). The VH domain from an antibody binding CD3as a T-cell engaging domain of the first component and the VL domainfrom an antibody binding CD3 as a T-cell engaging domain of the secondcomponent are capable of binding to each other when not bound to aninert binding partner and possessing the activity to engage a T-cell.

The patient is infused with the agent, which targets all B cells,healthy and malignant. Upon binding malignant cells, the agent comesinto contact with proteases whereby cleavage of the protease recognitiondomain releases the inert binding partners from both the first and thesecond T-cell engaging domains.

The malignant B cells that are bound by the now-activated two-componentsystem complex attracts the host immune system for cytolysis by T-cellsdue to the presence and activity of the complex of the first and secondT-cell engaging domains.

Example 5. Specific Embodiments of Two-Component Systems

A two-component system chosen from System A-E is prepared according toTable 3 and administered to a patient having cancer. If an item isdescribed as optional, the row of the table describes both two-componentsystems having or not having that item.

TABLE 6 Certain Embodiments of the Two-Component System A FirstComponent T-Cell Targeting Engaging Cleavage Moiety Moiety Site Inertbinding partner Optional Linker(s) & Location(s) Antibody V_(H) of AnyAny VH domain that For example, GGGGS (SEQ ID No: 85). targeting HER2antibody ADAM28 binds to the VL domain Located between the V_(H) andV_(L) of the targeting CD3 cleavage site of the T-cell engagingtargeting moiety, between the targeting domain without moiety and theinactive T-cell engaging creating any binding domain, and/or between theV_(H) and V_(L) of specificity the inactive T-cell engaging domain (SeeFIG. 1). Second Component Optional T-Cell Optional Targeting EngagingCleavage Optional Inert Moiety Moiety Site binding partner OptionalLinker(s) & Location(s) Antibody V_(L) of Any Any VH domain that Forexample, GGGGS (SEQ ID No: 85). targeting HER2 antibody ADAM28 binds tothe VL domain Located between the V_(H) and V_(L) of the targeting CD3cleavage site of the T-cell engaging targeting moiety, between thetargeting domain without moiety and the inactive T-cell engagingcreating any binding domain, and/or between the V_(H) and V_(L) ofspecificity the inactive T-cell engaging domain (See FIG. 1). B FirstComponent T-Cell Targeting Engaging Cleavage Moiety Moiety Site Inertbinding partner Optional Linker(s) & Location(s) antibody targetingV_(H) of Any Any VH domain that For example, GGGGS (SEQ ID No: 85).EGFR, such as antibody ADAM28 binds to the VL domain Located between theV_(H) and V_(L) of the Cetuximab targeting CD4 cleavage site of theT-cell engaging targeting moiety, between the targeting domain withoutmoiety and the inactive T-cell engaging creating any binding domain,and/or between the V_(H) and V_(L) of specificity the inactive T-cellengaging domain (See FIG. 1). Second Component Optional T-Cell OptionalTargeting Engaging Cleavage Optional Inert Moiety Moiety Site bindingpartner Optional Linker(s) & Location(s) antibody targeting V_(L) of AnyAny VH domain that For example, GGGGS (SEQ ID No: 85). EGFR, such asantibody ADAM28 binds to the VL domain Located between the V_(H) andV_(L) of the Cetuximab targeting CD4 cleavage site of the T-cellengaging targeting moiety, between the targeting domain without moietyand the inactive T-cell engaging creating any binding domain, and/orbetween the V_(H) and V_(L) of specificity the inactive T-cell engagingdomain (See FIG. 1). C First Component T-Cell Targeting EngagingCleavage Moiety Moiety Site Inert binding partner Optional Linker(s) &Location(s) antibody targeting V_(H) of Any Any VH domain that Forexample, GGGGS (SEQ ID No: 85). CD20, such as antibody ADAM28 binds tothe VL domain Located between the V_(H) and V_(L) of the Rituximabtargeting CD8 cleavage site of the T-cell engaging targeting moiety,between the targeting domain without moiety and the inactive T-cellengaging creating any binding domain, and/or between the V_(H) and V_(L)of specificity the inactive T-cell engaging domain (See FIG. 1). SecondComponent Optional T-Cell Optional Targeting Engaging Cleavage OptionalInert Moiety Moiety Site binding partner Optional Linker(s) &Location(s) antibody targeting V_(L) of Any Any VH domain that Forexample, GGGGS (SEQ ID No: 85). CD20, such as antibody ADAM28 binds tothe VL domain Located between the V_(H) and V_(L) of the Rituximabtargeting CD8 cleavage site of the T-cell engaging targeting moiety,between the targeting domain without moiety and the inactive T-cellengaging creating any binding domain, and/or between the V_(H) and V_(L)of specificity the inactive T-cell engaging domain (See FIG. 1). D FirstComponent T-Cell Targeting Engaging Cleavage Moiety Moiety Site Inertbinding partner Optional Linker(s) & Location(s) antibody targetingV_(H) of Any Any VH domain that For example, GGGGS (SEQ ID No: 85).CD22, such as antibody ADAM28 binds to the VL domain Located between theV_(H) and V_(L) of the Inotuzumab targeting cleavage site of the T-cellengaging targeting moiety, between the targeting CD28 domain withoutmoiety and the inactive T-cell engaging creating any binding domain,and/or between the V_(H) and V_(L) of specificity the inactive T-cellengaging domain (See FIG. 1). Second Component Optional T-Cell OptionalTargeting Engaging Cleavage Optional Inert Moiety Moiety Site bindingpartner Optional Linker(s) & Location(s) antibody targeting V_(L) of AnyAny VH domain that For example, GGGGS (SEQ ID No: 85). CD22, such asantibody ADAM28 binds to the VL domain Located between the V_(H) andV_(L) of the Inotuzumab targeting cleavage site of the T-cell engagingtargeting moiety, between the targeting CD28 domain without moiety andthe inactive T-cell engaging creating any binding domain, and/or betweenthe V_(H) and V_(L) of specificity the inactive T-cell engaging domain(See FIG. 1). E First Component T-Cell Targeting Engaging CleavageMoiety Moiety Site Inert binding partner Optional Linker(s) &Location(s) antibody targeting V_(H) of Any Any VH domain that Forexample, GGGGS (SEQ ID No: 85). CD33, such as antibody ADAM28 binds tothe VL domain Located between the V_(H) and V_(L) of the Gemtuzumabtargeting T cleavage site of the T-cell engaging targeting moiety,between the targeting cell receptor domain without moiety and theinactive T-cell engaging (TCR) creating any binding domain, and/orbetween the V_(H) and V_(L) of specificity the inactive T-cell engagingdomain (See FIG. 1). Second Component Optional T-Cell Optional TargetingEngaging Cleavage Optional Inert Moiety Moiety Site binding partnerOptional Linker(s) & Location(s) antibody targeting V_(L) of Any Any VHdomain that For example, GGGGS (SEQ ID No: 85). CD33, such as antibodyADAM28 binds to the VL domain Located between the V_(H) and V_(L) of theGemtuzumab targeting T cleavage site of the T-cell engaging targetingmoiety, between the targeting cell receptor domain without moiety andthe inactive T-cell engaging (TCR) creating any binding domain, and/orbetween the V_(H) and V_(L) of specificity the inactive T-cell engagingdomain (See FIG. 1).

Example 6. Embodiments

The following numbered items provide embodiments as described herein,though the embodiments recited here are not limiting.

Item 1. A two-component system for treating a condition characterized bythe presence of unwanted cells comprising:

-   -   a. a first component comprising a targeted T-cell engaging agent        comprising:        -   i. a first targeting moiety that is capable of targeting the            unwanted cells;        -   ii. a first T-cell engaging domain capable of T-cell            engaging activity when binding a second T-cell engaging            domain, wherein the second T-cell engaging domain is not            part of the first component;        -   iii. a first inert binding partner for the first T-cell            engaging domain binding to the first T-cell engaging domain            such that the first T-cell engaging domain does not bind to            the second T-cell engaging domain unless the inert binding            partner is removed; and        -   iv. a cleavage site separating the first T-cell engaging            domain and the first inert binding partner, wherein the            cleavage site is:            -   (1) cleaved by an enzyme expressed by the unwanted                cells;            -   (2) cleaved through a pH-sensitive cleavage reaction                inside the unwanted cell;            -   (3) cleaved by a complement-dependent cleavage reaction;                or            -   (4) cleaved by a protease that is colocalized to the                unwanted cell by a targeting moiety that is the same or                different from the targeting moiety in the agent,    -   b. a second component comprising a second T-cell engaging domain        capable of T-cell engaging activity when binding the first        T-cell engaging domain,        wherein the first and second T-cell engaging domains are capable        of binding when neither is bound to an inert binding partner.

Item 2. The two-component system of item 1, wherein the second componentfurther comprises a second targeting moiety that is capable of targetingthe unwanted cells.

Item 3. The two-component system of any one of items 1-2, wherein thesecond component further comprises a second inert binding partner forthe second T-cell engaging domain binding to the second T-cell engagingdomain such that the second T cell engaging domain does not bind to thefirst T-cell engaging domain unless the inert binding partner is removedand

-   -   a. a cleavage site separating the second T-cell engaging domain        and the second inert binding partner, wherein the cleavage site        is:        -   i. cleaved by an enzyme expressed by the unwanted cells;        -   ii. cleaved through a pH-sensitive cleavage reaction inside            the unwanted cell;        -   iii. cleaved by a complement-dependent cleavage reaction; or        -   iv. cleaved by a protease that is colocalized to the            unwanted cell by a targeting moiety that is the same or            different from the targeting moiety in the agent,            wherein cleavage of the cleavage site causes loss of the            inert binding partner and complementation with the first            T-cell engaging domain of the two-component system.

Item 4. The two-component system of any one of items 1-3, wherein thefirst and the second targeting moieties are the same.

Item 5. The two-component system of any one of items 1-3, wherein thefirst and the second targeting moieties are different.

Item 6. The two-component system of any one of items 1-5, wherein thefirst and second cleavage site are the same.

Item 7. The two-component system of any one of items 1-5, wherein thefirst and second cleavage site are different.

Item 8. The two-component system of any one of items 1-7, wherein atleast one cleavage site is a protease cleavage site.

Item 9. The two-component system of any one of items 1-8, wherein atleast one cleavage site is capable of being cleaved outside the unwantedcells.

Item 10. The two-component system of any one of items 1-9, wherein atleast one enzyme expressed by the unwanted cells is a protease.

Item 11. The two-component system of any one of items 1-10, wherein atleast one inert binding partner specifically binds the T-cell engagingdomain.

Item 12. The two-component system of any one of items 1-11, wherein atleast one inert binding partner is a VH or VL domain.

Item 13. The two-component system of any one of items 1-12, wherein

-   -   a. when the T-cell engaging domain is a VH domain, the inert        binding partner is a VL domain and    -   b. when the T-cell engaging domain is VL domain, the inert        binding partner is a VH domain.

Item 14. The two-component system of any one of items 1-13, wherein atleast one targeting moiety is an antibody or functional fragmentthereof.

Item 15. The two-component system of any one of items 1-14, wherein theat least one inert binding partner is capable of dissociation once atleast one cleavage site has been cleaved and after dissociation the twoT-cell engaging domains are capable of binding to each other andexhibiting T-cell engaging activity.

Item 16. The two-component system of item 1-15, wherein one T-cellengaging domain is a VH domain and the other T-cell engaging domain is aVL domain.

Item 17. A component for use in a two-component system for treating acondition characterized by the presence of unwanted cells comprising afirst targeted T-cell engaging agent comprising:

-   -   a. a targeting moiety that is capable of targeting the unwanted        cells;    -   b. a first T-cell engaging domain capable of T-cell engaging        activity when binding a second T-cell engaging domain, wherein        the second T-cell engaging domain is not part of the first        targeted T-cell engaging agent;    -   c. an inert binding partner for the first T-cell engaging domain        binding to the first T-cell engaging domain such that the first        T-cell engaging domain does not bind to the second T-cell        engaging domain unless the inert binding partner is removed; and    -   d. a cleavage site separating the first T-cell engaging domain        and the inert binding partner, wherein the cleavage site is:        -   i. cleaved by an enzyme expressed by the unwanted cells;        -   ii. cleaved through a pH-sensitive cleavage reaction inside            the unwanted cell;        -   iii. cleaved by a complement-dependent cleavage reaction; or        -   iv. cleaved by a protease that is colocalized to the            unwanted cell by a targeting moiety that is the same or            different from the targeting moiety in the agent,            wherein cleavage of the cleavage site causes loss of the            inert binding partner and allows for complementation with            the second T-cell engaging domain that is not part of the            agent.

Item 18. The component for use in a two-component system of item 17,wherein the cleavage site is a protease cleavage site.

Item 19. The component for use in a two-component system of any one ofitems 17-18, wherein the cleavage site is capable of being cleavedoutside the unwanted cells.

Item 20. The component for use in a two-component system of any one ofitems 17-19, wherein the enzyme expressed by the unwanted cells is aprotease.

Item 21. The component for use in a two-component system of any one ofitems 17-20, wherein at least one inert binding partner specificallybinds the T-cell engaging domain.

Item 22. The component for use in a two-component system of any one ofitems 17-21, wherein the inert binding partner is a VH or VL domain.

Item 23. The component for use in a two-component system of any one ofitems 17-22, wherein

-   -   a. when the T-cell engaging domain is a VH domain, the inert        binding partner is a VL domain and    -   b. when the T-cell engaging domain is VL domain, the inert        binding partner is a VH domain.

Item 24. The component for use in a two-component system of any one ofitems 17-23, wherein the targeting moiety is an antibody or functionalfragment thereof.

Item 25. A set of nucleic acid molecules encoding the first and secondcomponent of the two component system of any one of items 1-16.

Item 26. A nucleic acid molecule encoding the component for use in atwo-component system of any one of items 17-24.

Item 27. A method of treating a disease in a patient characterized bythe presence of unwanted cells comprising administering thetwo-component system of any one of items 1-16 to the patient.

Item 28. A method of targeting an immune response of a patient tounwanted cells comprising administering the two-component system of anyone of items 1-16 to the patient.

Item 29. The method of any one of items 27-28, wherein the unwantedcells are cancer cells.

Item 30. The method of item 29, wherein the cancer is any one of breastcancer, ovarian cancer, endometrial cancer, cervical cancer, bladdercancer, renal cancer, melanoma, lung cancer, prostate cancer, testicularcancer, thyroid cancer, brain cancer, esophageal cancer, gastric cancer,pancreatic cancer, colorectal cancer, liver cancer, leukemia, myeloma,nonHodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia, acutelymphoblastic leukemia, chronic lymphoblastic leukemia,lymphoproliferative disorder, myelodysplastic disorder,myeloproliferative disease or premalignant disease.

EQUIVALENTS

The foregoing written specification is considered to be sufficient toenable one skilled in the art to practice the embodiments. The foregoingdescription and Examples detail certain embodiments and describes thebest mode contemplated by the inventors. It will be appreciated,however, that no matter how detailed the foregoing may appear in text,the embodiment may be practiced in many ways and should be construed inaccordance with the appended claims and any equivalents thereof.

As used herein, the term about refers to a numeric value, including, forexample, whole numbers, fractions, and percentages, whether or notexplicitly indicated. The term about generally refers to a range ofnumerical values (e.g., +/−5-10% of the recited range) that one ofordinary skill in the art would consider equivalent to the recited value(e.g., having the same function or result). When terms such as at leastand about precede a list of numerical values or ranges, the terms modifyall of the values or ranges provided in the list. In some instances, theterm about may include numerical values that are rounded to the nearestsignificant figure.

1.-20. (canceled)
 21. A kit or composition for treating cancer in apatient comprising: a. a first component comprising a targeted T-cellbinding agent comprising: i. a first targeting moiety that binds a tumorantigen expressed by the cancer; ii. a first T-cell binding domaincapable of T-cell binding activity when binding a second T-cell bindingdomain, wherein the second T-cell binding domain is not part of thefirst component, and wherein the first T-cell binding domain is either aVH domain or VL domain; iii. a first inert binding partner for the firstT-cell binding domain binding to the first T-cell binding domain suchthat the first T-cell binding domain does not bind to the second T-cellbinding domain unless the inert binding partner is removed, wherein ifthe first T-cell binding domain is a VH domain, the inert bindingpartner is a VL domain and if the first T-cell binding domain is a VLdomain, the inert binding partner is a VH domain; and iv. a proteasecleavage site separating the first T-cell binding domain and the firstinert binding partner, wherein the protease cleavage site is capable ofreleasing the inert binding domain from the T-cell binding domain in thepresence of a protease: (1) expressed by the cancer; (2) colocalized tothe cancer by a targeting moiety that binds a tumor antigen expressed bythe cancer and that is the same or different from the targeting moietyin the agent, a second component comprising a second T-cell bindingdomain capable of T-cell binding activity when binding the first T-cellbinding domain, wherein the first and second T-cell binding domains arecapable of binding CD3 or the T cell receptor (TCR) when neither isbound to an inert binding partner, and further wherein if the firstT-cell binding domain is a VH domain, the second T-cell binding domainis a VL domain and if the first T-cell binding domain is a VL domain,the second T-cell binding domain is a VH domain, and wherein the secondcomponent optionally further comprises a second targeting moiety thatbinds a tumor antigen expressed by the cancer.
 22. The kit orcomposition of claim 21, wherein the second component further comprisesa second targeting moiety that binds a tumor antigen expressed by thecancer.
 23. The kit or composition of claim 22, wherein the first andsecond targeting moiety target different tumor antigens.
 24. The kit orcomposition of claim 22, wherein the first and second targeting moietytarget different epitopes on the same tumor antigen.
 25. The kit orcomposition of claim 21, wherein the first and/or second targetingmoiety comprises an antibody or antigen fragment.
 26. The kit orcomposition of claim 21, wherein the first and/or second targetingmoiety comprises an aptamer.
 27. The kit or composition of claim 26,wherein the aptamer comprises DNA.
 28. The kit or composition of claim27, wherein the aptamer is single-stranded.
 29. The kit or compositionof claim 26, wherein the aptamer is a target cell-specific aptamerselected from a random candidate library.
 30. The kit or composition ofclaim 26, wherein the aptamer is an anti-EGFR aptamer.
 31. The kit orcomposition of claim 30, wherein the anti-EGFR aptamer comprises any oneof SEQ ID NOs: 95-164.
 32. The kit or composition of claim 26, whereinthe aptamer binds to the target on the unwanted cell with a K_(d) from 1picomolar to 500 nanomolar.
 33. The kit or composition of claim 32,wherein the aptamer binds to the target on the unwanted cell with aK_(d) from 1 picomolar to 100 nanomolar.
 34. The kit or composition ofclaim 23, wherein the first and/or second targeting moiety comprisesIL-2, IL-4, IL-6, α-MSH, transferrin, folic acid, EGF, TGF, PD1, IL-13,stem cell factor, insulin-like growth factor (IGF), or CD40.
 35. The kitor composition of claim 34, wherein the first and/or second targetingmoiety comprises a full-length sequence of IL-2, IL-4, IL-6, α-MSH,transferrin, folic acid, EGF, TGF, PD1, IL-13, stem cell factor,insulin-like growth factor (IGF), or CD40.
 36. The kit or composition ofclaim 34, wherein the first and/or second targeting moiety comprises atruncated form, analog, variant, or derivative of IL-2, IL-4, IL-6,α-MSH, transferrin, folic acid, EGF, TGF, PD1, IL-13, stem cell factor,insulin-like growth factor (IGF), or CD40.
 37. The kit or composition ofclaim 34, wherein the first and/or second targeting moiety binds theIL-2 receptor, IL-4, IL-6, melanocyte stimulating hormone receptor (MSHreceptor), transferrin receptor (TR), folate receptor 1 (FOLR), folatehydroxylase (FOLH1), EGF receptor, PD-L1, PD-L2, IL-13R, CXCR4, IGFR, orCD40L.
 38. The kit or composition of claim 22, wherein the secondtargeting moiety that binds a tumor antigen expressed by the cancercomprises an aptamer; antibody or antigen binding fragment thereof;IL-2, IL-4, IL-6, α-MSH, transferrin, folic acid, EGF, TGF, PD1, IL-13,stem cell factor, insulin-like growth factor (IGF), or CD40.
 39. The kitor composition of claim 22, wherein the second component furthercomprises a second inert binding partner for the second T-cell bindingdomain binding to the second T-cell binding domain such that the secondT cell binding domain does not bind to the first T-cell binding domainunless the inert binding partner is removed, wherein if the secondT-cell binding domain is a VH domain, the inert binding partner is a VLdomain and if the second T-cell binding domain is a VL domain, the inertbinding partner is a VH domain and a. a protease cleavage siteseparating the second T-cell binding domain and the second inert bindingpartner, wherein the protease cleavage site is (i) cleaved by a proteaseexpressed by the cancer (ii) cleaved by a protease that is colocalizedto the cancer by a targeting moiety that binds a tumor antigen expressedby the cancer and that is the same or different from the targetingmoiety in the agent, wherein cleavage of the protease cleavage sitecauses loss of the inert binding partner and complementation with thefirst T-cell binding domain of the kit or composition.
 40. The kit orcomposition of claim 39, wherein the first and the second targetingmoieties are different.
 41. The kit or composition of claim 39, whereinthe protease cleavage sites of the first component and second componentare different.
 42. The kit or composition of claim 39, wherein theprotease cleavage sites of the first component and second component arecleaved by a protease expressed by the cancer.
 43. The kit orcomposition of claim 39, wherein the protease cleavage sites of thefirst component and/or second component are cleaved by a protease thatis colocalized to the cancer by a targeting moiety that binds a tumorantigen expressed by the cancer expressed by the cancer and that is thesame or different from the targeting moiety in the agent.
 44. The kit orcomposition of claim 39, wherein each inert binding partner is capableof dissociation once at least one protease cleavage site for each inertbinding partner has been cleaved and after dissociation the two T-cellbinding domains are capable of binding to each other and exhibitingT-cell binding activity.
 45. A component for use in a kit or compositionfor treating cancer in a patient comprising a first targeted T-cellbinding agent comprising: a. a targeting moiety that binds a tumorantigen expressed by the cancer; b. a first T-cell binding domaincapable of T-cell binding activity when binding a second T-cell bindingdomain, wherein the second T-cell binding domain is not part of thefirst targeted T-cell binding agent, and wherein the first T-cellbinding domain is either a VH domain or VL domain and wherein the firstT-cell binding domain and the second T-cell binding domain are capableof binding CD3 or TCR; c. an inert binding partner for the first T-cellbinding domain binding to the first T-cell binding domain such that thefirst T-cell binding domain does not bind to the second T-cell bindingdomain unless the inert binding partner is removed, wherein if the firstT-cell binding domain is a VH domain, the inert binding partner is a VLdomain and if the first T-cell binding domain is a VL domain, the inertbinding partner is a VH domain; and a protease cleavage site separatingthe first T-cell binding domain and the inert binding partner, whereinthe cleavage site is cleaved by a protease that is colocalized to thecancer by that binds a tumor antigen expressed by the cancer and that isthe same or different from the targeting moiety in the agent, whereincleavage of the protease cleavage site causes loss of the inert bindingpartner and allows for complementation with the second T-cell bindingdomain that is not part of the agent, further wherein if the firstT-cell binding domain is a VH domain, the second T-cell binding domainis a VL domain and if the first T-cell binding domain is a VL domain,the second T-cell binding domain is a VH domain.
 46. A set of nucleicacid molecules encoding the first and second components of the kit orcomposition of claim
 22. 47. A nucleic acid molecule encoding the firsttargeted T-cell binding agent of claim
 45. 48. A method of treatingcancer expressing a tumor antigen that binds the first targeting moietyin a patient comprising administering the composition of claim 21 to thepatient.
 49. A method of treating cancer expressing a tumor antigen thatbinds the first targeting moiety in a patient comprising administeringthe composition of claim 39 to the patient.
 50. The method of claim 49,wherein the cancer expressing a tumor antigen that binds the firsttargeting moiety is any one of breast cancer, ovarian cancer,endometrial cancer, cervical cancer, bladder cancer, renal cancer,melanoma, lung cancer, prostate cancer, testicular cancer, thyroidcancer, brain cancer, esophageal cancer, gastric cancer, pancreaticcancer, colorectal cancer, liver cancer, leukemia, myeloma, nonHodgkinlymphoma, Hodgkin lymphoma, acute myeloid leukemia, acute lymphoblasticleukemia, chronic lymphoblastic leukemia, lymphoproliferative disorder,myelodysplastic disorder, myeloproliferative disease or premalignantdisease.
 51. A method of targeting T cells expressing CD3 or TCR tocancer expressing a tumor antigen that binds the first targeting moietyin a patient comprising administering the composition of claim 39 to thepatient.
 52. The kit or composition of claim 25, wherein the antibody orantigen binding fragment thereof binds Her2/Neu; CD22; PSMA; CD30; CD20;CD33; CD80; CD86; CD2; CA125; Carbonic Anhydrase IX; CD70; CD74; CD56;CD40; CD19; c-met/HGFR; TRAIL-R1; DRS; PD-1; IGF-1R; VEGF-R2; PSCA;MUC1; CanAg; Mesothelin; P-cadherin; Myostatin; Cripto; ACVRL 1/ALK1;MUCSAC; CEACAM; CD137; CXCR4; Neuropilin 1; Glypicans; HERS/EGFR;PDGFRa; EphA2; CD38; CD138/Syndecan1; α4-integrin; EpCAM, ADAM17, CD59,Integrin αV, Integrin αVβ3, MCP-1, PCLA, RANKL, RG1, SLC44A4, STEAP-1,VEGF-C, CCN1, CD44, CD98, c-RET, DLL4, Episialin, GPNMB, Integrin α6β4,LFL2, LIV-1, Ly6E, MUC18, NRP1, Phosphatidylserine, PRLR, TACSTD-2,Tenascin C, TWEAKR, VANGL2, PD-L1, PD-L2, BCMA, DKK-1, ICAM-1, GRP78,FGFR3, SLAMF6, CD48, CD71, APRIL, DR5, CD37, HLA-DR, CD70b, CAIX, TPBG,ENPP3, FGFR1, VEGFR-2, CLDN18, GCC, C242, FGFR2, GPR49, IGFR, ALK, GD2,EGFRvIII, CD4, CD5, IL-3Ra, Integrin α5β1, Lewis y/b antigen, EGFL7,NaPi2b, flt4, CD133, CD123, CD45, c-Kit, Lewis Y, Siglec-15, FLT-3,CEACAM1, Cadherin-19, GM3, TYRP1, GD3, MUC5A, CLDN6, Glypican-3, FGFR4,PIVKA-II, PLVAP, Progastrin, CEA, CLDN1, A33, CK8, or FAP.
 53. The kitor composition of claim 25, wherein the antibody or antigen bindingfragment thereof is an anti-epidermal growth factor receptor antibody,an anti-Her2 antibody, an anti-CD20 antibody, an anti-CD22 antibody, ananti-CD70 antibody, an anti-CD33 antibody, an anti-MUC1 antibody, ananti-CD40 antibody, an anti-CD74 antibody, an anti-P-cadherin antibody,an anti-EpCAM antibody, an anti-CD138 antibody, an anti-E-cadherinantibody, an anti-CEA antibody, an anti-FGFR3 antibody, an antiα4-integrin antibody, an anti-CD80 antibody, an anti-mucin core proteinantibody, an anti-transferrin antibody, an anti-gp95/97 antibody, ananti-p-glycoprotein antibody, an anti-TRAIL-R1 antibody, an anti-DR5antibody, an anti-IL-4 antibody, an anti-IL-6 antibody, an anti-CD19antibody, an anti-PSMA antibody, an anti-PSCA antibody, an anti-Criptoantibody, an anti-PD-L1 antibody, an anti-IGF-1R antibody, an anti-CD38antibody, an anti-CD133 antibody, an anti-CD123 antibody, an anti-CD49dantibody, an anti-glypican 3 antibody, an anti-cMet antibody, or ananti-IL-13R antibody.
 54. The kit or composition of claim 25, whereinthe antibody or antigen binding fragment thereof is Cetuximab,Rituximab, Inotuzumab, G544, BU59, hp67.6, Gemtuzumab, GP1.4, SM3, orNatalizumab.